aspirin has been researched along with Ischemia in 265 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Ischemia: A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the association of mandatory reporting of CYP2C19 pharmacogenomic testing, provided to investigators with no direct recommendations on how to use these results, with changes in P2Y12 inhibitor use, particularly clopidogrel, in the Randomized Trial to Compare the Safety of Rivaroxaban vs Aspirin in Addition to Either Clopidogrel or Ticagrelor in Acute Coronary Syndrome (GEMINI-ACS-1) clinical trial." | 9.30 | P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. ( Bode, C; Cornel, JH; Gibson, CM; James, S; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Plotnikov, AN; Povsic, TJ; Rockhold, FW; Roe, MT; Steg, PG; Welsh, RC; White, J, 2019) |
| "In patients with acute minor ischemic stroke or high-risk transient ischemic attack enrolled in the POINT trial (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke [POINT] Trial), the combination of clopidogrel and aspirin for 90 days reduced major ischemic events but increased major hemorrhage in comparison to aspirin alone." | 9.30 | Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke. ( Albers, GW; Barsan, WG; Cucchiara, BL; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Kleindorfer, DO; Lindblad, AS; Lutsep, HL; Palesch, YY; Pearson, C; Sethi, P; Vora, N; Zurita, KG, 2019) |
| " The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days." | 9.27 | Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018) |
| "PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) randomized 21,162 patients with prior MI (1 to 3 years) to ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, or placebo, all on a background of low-dose aspirin." | 9.22 | Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. ( Abola, MTB; Aylward, P; Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Corbalán, R; Dalby, A; Dellborg, M; Goodrich, E; Held, P; Jensen, EC; Kuder, J; López-Sendón, J; Nicolau, JC; Parkhomenko, A; Sabatine, MS; Špinar, J; Steg, PG; Storey, RF, 2016) |
| "The purpose of this study was to examine whether aspirin regulates vascular endothelial function following ischemia." | 9.16 | Regulation of blood flow by aspirin following muscle ischemia. ( Cameron, SJ; Goulopoulou, S; Kanaley, JA; Weil, BR, 2012) |
| "Extended release dipyridamole (ERD) is widely used in patients after ischaemic stroke; however, the ability of this antithrombotic agent to be stored in different blood cells has never been explored in post-stroke patients." | 9.14 | Distribution of dipyridamole in blood components among post-stroke patients treated with extended release formulation. ( Atar, OD; Booze, C; Eisert, C; Hanley, D; Sabaeva, E; Serebruany, V, 2009) |
| "Headache is reported by about one third of patients using dipyridamole (DP) after stroke or TIA." | 9.11 | Dipyridamole and headache--a pilot study of initial dose titration. ( Husted, S; Lindgren, A; Staaf, G; Ziegler, B, 2004) |
| " From 1974 to 1986 we treated 20 symptomatic ET patients with microvascular circulation disturbances including erythromelalgia (N = 18), atypical or typical transient ischemic attacks (N = 6), or acute coronary ischemic syndrome (N = 3) with aspirin and one course of busulfan." | 9.09 | Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia. ( Michiels, JJ, 1999) |
| " We sought to determine whether clopidogrel compared with aspirin decreases the need for rehospitalization for ischemia and bleeding." | 9.09 | Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000) |
| " Although a 150 mg dose of aspirin reduced urinary dinor-TxB2 levels by over 75 per cent, it had no effect on the course of the chronic recurrent form of angina pectoris due to vasospasm ("vasotonic angina")." | 9.05 | Thromboxane A2 in vasotonic angina pectoris: evidence from direct measurements and inhibitor trials. ( FitzGerald, GA; Friesinger, GC; Maas, RL; Oates, JA; Roberts, LJ; Robertson, D; Robertson, RM, 1981) |
| "PubMed and MEDLINE searches (up to January 2010) were performed to identify primary literature, using search terms including aspirin, stroke prevention, acute ischemic stroke, acetylsalicylic acid, atrial fibrillation, myocardial infarction, and carotid endarterectomy." | 8.86 | Aspirin dosing for the prevention and treatment of ischemic stroke: an indication-specific review of the literature. ( Ansara, AJ; Arif, SA; Koehler, JM; Nisly, SA; Nordmeyer, ST, 2010) |
| "In the secondary prevention of cardiovascular, cerebrovascular, and ischemic events, the evidence supports that the benefits of aspirin treatment significantly outweigh the risk of a major hemorrhage." | 8.82 | Risk of hemorrhagic stroke with aspirin use: an update. ( Gorelick, PB; Weisman, SM, 2005) |
| "In patients with ACS who were free from ischemic or major bleeding events during the first 3 months after PCI, the subsequent clopidogrel treatment might reduce minor bleeding events without increasing the risk of MACCE compared with ticagrelor." | 8.31 | Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China. ( Li, X; Lin, Y; Peng, W; Zhang, Y, 2023) |
| "The goal of this work was to investigate the short-term time-course benefit and risk of ticagrelor with aspirin in acute mild-moderate ischemic stroke or high-risk TIA in The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and ASA for Prevention of Stroke and Death (THALES) trial." | 8.12 | Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack. ( Amarenco, P; Denison, H; Evans, SR; Himmelmann, A; James, S; Johnston, SC; Knutsson, M; Ladenvall, P; Li, H; Molina, CA; Pan, Y; Wang, Y, 2022) |
| " This study aims to compare the impact of aspirin (ASA) monotherapy, P2Y12 monotherapy, and DAPT on limb salvage (LS), amputation-free survival (AFS), and overall survival (OS) in patients undergoing lower extremity peripheral endovascular intervention (PVI) for chronic limb-threatening ischemia (CLTI)." | 8.12 | P2Y12 inhibitor monotherapy is associated with superior outcomes as compared with aspirin monotherapy in chronic limb-threatening ischemia. ( Dosluoglu, HH; Dryjski, ML; Fakhoury, E; Harris, LM; Khan, SZ; Montross, B; O'Brien-Irr, MS; Rivero, M, 2022) |
| "Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial." | 7.96 | Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. ( Bikdeli, B; Cho, J; Gupta, A; Hripcsak, G; Kim, J; Krumholz, HM; Londhe, A; Madigan, D; Park, J; Park, RW; Reich, CG; Rho, Y; Ryan, PB; Schuemie, M; Siapos, A; Suchard, MA; Weaver, J; You, SC, 2020) |
| "The goal of this study is to establish the prevalence of high on-treatment platelet reactivity to aspirin (HPRA) and clopidogrel (HPRC) in patients with critical limb ischemia (CLI)." | 7.88 | Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia. ( Al-Asady, N; Caro, J; Clavijo, LC; Dhillon, A; Matthews, RV; Rowe, V; Shavelle, DM; Tun, H, 2018) |
| "Background Dual antithrombotic therapy comprising a vitamin K antagonist (VKA) plus clopidogrel reduces the incidence of major bleeding compared with triple therapy (VKA + clopidogrel + aspirin) in acute coronary syndrome (ACS) patients with atrial fibrillation (AF), with a similar thrombotic risk." | 7.88 | Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation. ( Bonello, L; Camoin-Jau, L; Gaubert, M; Laine, M; Paganelli, F; Resseguier, N, 2018) |
| "BACKGROUND To investigate the combination of beraprost sodium (BPS) and aspirin in the treatment of acute ischemic stroke (AIS)." | 7.85 | Beneficial Effect of Beraprost Sodium Plus Aspirin in the Treatment of Acute Ischemic Stroke. ( Chen, S; Chen, W; He, W; Li, S; Wei, D; Xie, S, 2017) |
| " MIAs were frequently preceded or followed by ocular ischemic events of blurred vision, scotomas, transient flashing of the eyes, and sudden transient partial blindness preceded or followed erythromelalgia in the toes or fingers." | 7.81 | Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera. ( Berneman, Z; De Raeve, H; Gadisseur, A; Lam, KH; Michiels, JJ; Schroyens, W, 2015) |
| "National practice guidelines recommend early aspirin administration to reduce mortality in acute coronary syndrome (ACS)." | 7.81 | Prehospital aspirin administration for acute coronary syndrome (ACS) in the USA: an EMS quality assessment using the NEMSIS 2011 database. ( Govindarajan, P; Mercer, MP; Tataris, KL, 2015) |
| "Aspirin, when compared to placebo and controls, significantly increased muscle interstitial oedema when given orally and intravenously." | 7.69 | Aspirin increases tissue oedema after skeletal muscle ischaemia and reperfusion. ( Braithwaite, BD; Earnshaw, JJ; Gelabert, H; Moore, WS; Petrik, PV; Pollen, DN; Quinones-Baldrich, WJ, 1996) |
| "This study was performed to determine the relationship between net ion fluxes across the rat gastric mucosa and gastric mucosal damage after gastric ischemia and after intravenous administration of acetylsalicylic acid, and to determine the effect of cimetidine on these parameters." | 7.67 | Effect of cimetidine on net ion fluxes across the rat gastric mucosa during mucosal damage after gastric ischemia and after intravenous acetylsalicylic acid. ( Parsons, ME; Pipkin, G; Price, CA, 1984) |
| "The primary outcome was restenosis documented by magnetic resonance (MR) angiography or duplex imaging at 12 months." | 6.76 | Batroxobin plus aspirin reduces restenosis after angioplasty for arterial occlusive disease in diabetic patients with lower-limb ischemia. ( Cheng, YS; Li, MH; Liu, F; Tan, HQ; Wang, J; Wang, JB; Zhao, JG; Zhu, YQ, 2011) |
| "Patients with lower extremity peripheral artery disease (PAD) are at increased risk of major adverse limb events (MALE)." | 6.72 | The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials. ( Costa, G; Gonçalves, L; Teixeira, R, 2021) |
| "5 mg twice daily to aspirin or dual antiplatelet therapy significantly reduced this risk, with an increase in the bleeding risk, but had a favorable benefit risk for patients treated with bypass surgery, regardless of conduit type." | 5.69 | Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits. ( Anand, SS; Bauersachs, RM; Berkowitz, SD; Bonaca, MP; Capell, WH; Chung, J; Conte, MS; Debus, S; Dorigo, W; Govsyeyev, N; Gudz, I; Haskell, LP; Hess, CN; Jaeger, N; Krievins, D; Mills, J; Moll, F; Muehlhofer, E; Nehler, M; Norgren, L; Patel, MR; Piffaretti, G; Powell, R; Sillesen, H; Szalay, D; Szarek, M; Wohlauer, M, 2023) |
| "The Clopidogrel and Acetylsalicylic Acid in Bypass Surgery for Peripheral Arterial Disease (CASPAR) trial is the only large, double-blind, placebo-controlled trial of dual antiplatelet therapy (DAPT) versus aspirin in patients with peripheral artery disease (PAD) after lower extremity revascularization (LER)." | 5.51 | Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD. ( Anand, SS; Bauersachs, RM; Berkowitz, SD; Bonaca, MP; Debus, ES; Haskell, LP; Muehlhofer, E; Nehler, MR; Patel, MR; Szarek, M, 2022) |
| " Guideline-recommended dual antiplatelet therapy (DAPT; aspirin plus prasugrel/ticagrelor) for 12 months in acute coronary syndrome (ACS) patients increases bleeding, with East Asians (EAs) exhibiting higher bleeding and lower ischemic risk, compared with non-East Asians (nEAs)." | 5.41 | Comparison of De-escalation of DAPT Intensity or Duration in East Asian and Western Patients with ACS Undergoing PCI: A Systematic Review and Meta-analysis. ( Farag, M; Gorog, DA; Jeong, YH; Jeyalan, V; Markides, RIL; Navarese, EP, 2023) |
| "5 mg twice daily plus aspirin was associated with a significantly lower incidence of the composite outcome of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or death from cardiovascular causes than aspirin alone." | 5.34 | Rivaroxaban in Peripheral Artery Disease after Revascularization. ( Anand, SS; Bauersachs, RM; Berkowitz, SD; Bonaca, MP; Brodmann, M; Capell, WH; Debus, ES; Diao, L; Diaz, R; Fanelli, F; Gudz, I; Haskell, LP; Hess, CN; Hiatt, WR; Jaeger, N; Kittelson, JM; Krievins, DK; Mátyás, L; Muehlhofer, E; Nehler, MR; Pap, AF; Patel, MR, 2020) |
| "Aspirin was administered for vascular event prevention." | 5.32 | Aspirin withdrawal and acute lower limb ischemia. ( Albaladejo, P; Castier, Y; Francis, F; Geeraerts, T; Lesèche, G; Marty, J, 2004) |
| "To investigate the association of mandatory reporting of CYP2C19 pharmacogenomic testing, provided to investigators with no direct recommendations on how to use these results, with changes in P2Y12 inhibitor use, particularly clopidogrel, in the Randomized Trial to Compare the Safety of Rivaroxaban vs Aspirin in Addition to Either Clopidogrel or Ticagrelor in Acute Coronary Syndrome (GEMINI-ACS-1) clinical trial." | 5.30 | P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. ( Bode, C; Cornel, JH; Gibson, CM; James, S; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Plotnikov, AN; Povsic, TJ; Rockhold, FW; Roe, MT; Steg, PG; Welsh, RC; White, J, 2019) |
| "In patients with acute minor ischemic stroke or high-risk transient ischemic attack enrolled in the POINT trial (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke [POINT] Trial), the combination of clopidogrel and aspirin for 90 days reduced major ischemic events but increased major hemorrhage in comparison to aspirin alone." | 5.30 | Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke. ( Albers, GW; Barsan, WG; Cucchiara, BL; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Kleindorfer, DO; Lindblad, AS; Lutsep, HL; Palesch, YY; Pearson, C; Sethi, P; Vora, N; Zurita, KG, 2019) |
| " The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days." | 5.27 | Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018) |
| " Clinical equipoise also persists around questions such as the utility of dual antiplatelet therapy in conjunction with rivaroxaban after high-risk endovascular interventions and the optimal therapy for patients experiencing acute limb ischemia." | 5.22 | Antithrombotic Therapy in Peripheral Artery Disease: Risk Stratification and Clinical Decision Making. ( Anand, SS; Chan, N; Kaplovitch, E; McClure, GR, 2022) |
| " The prediction rule assigned 1 point each for myocardial infarction at presentation, prior myocardial infarction or PCI, diabetes, stent diameter less than 3 mm, smoking, and paclitaxel-eluting stent; 2 points each for history of congestive heart failure/low ejection fraction and vein graft intervention; -1 point for age 65 to younger than 75 years; and -2 points for age 75 years or older." | 5.22 | Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. ( Apruzzese, PK; Camenzind, E; Cohen, DJ; Cutlip, DE; Gershlick, AH; Kereiakes, DJ; Massaro, JM; Mauri, L; Normand, SL; Rinaldi, MJ; Secemsky, EA; Song, Y; Spertus, JA; Steg, PG; Wijns, W; Yeh, RW, 2016) |
| "PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) randomized 21,162 patients with prior MI (1 to 3 years) to ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, or placebo, all on a background of low-dose aspirin." | 5.22 | Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. ( Abola, MTB; Aylward, P; Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Corbalán, R; Dalby, A; Dellborg, M; Goodrich, E; Held, P; Jensen, EC; Kuder, J; López-Sendón, J; Nicolau, JC; Parkhomenko, A; Sabatine, MS; Špinar, J; Steg, PG; Storey, RF, 2016) |
| "The purpose of this study was to examine whether aspirin regulates vascular endothelial function following ischemia." | 5.16 | Regulation of blood flow by aspirin following muscle ischemia. ( Cameron, SJ; Goulopoulou, S; Kanaley, JA; Weil, BR, 2012) |
| "Extended release dipyridamole (ERD) is widely used in patients after ischaemic stroke; however, the ability of this antithrombotic agent to be stored in different blood cells has never been explored in post-stroke patients." | 5.14 | Distribution of dipyridamole in blood components among post-stroke patients treated with extended release formulation. ( Atar, OD; Booze, C; Eisert, C; Hanley, D; Sabaeva, E; Serebruany, V, 2009) |
| "In a double-blind randomized controlled trial, 108 patients undergoing infrainguinal revascularization or amputation for critical limb ischemia were maintained on aspirin (75 mg daily) and randomized to clopidogrel (600 mg prior to surgery, and 75 mg daily for 3 days; n = 50) or matched placebo (n = 58)." | 5.14 | Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia. ( Burdess, A; Dawson, AR; Fox, KA; Garden, OJ; Murie, JA; Newby, DE; Nimmo, AF, 2010) |
| "After successful PTA, 275 patients with symptomatic peripheral arterial disease (claudication or critical limb ischemia) and femoropopliteal obstructions were randomized to receive either 2500 IU of dalteparin subcutaneously for 3 months plus 100 mg of aspirin daily (n = 137), or 100 mg aspirin daily alone (n = 138)." | 5.12 | Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial. ( Amann-Vesti, BR; Banyai, M; Koppensteiner, R; Meier, T; Pfammatter, T; Rousson, V; Spring, S; van der Loo, B, 2006) |
| "Headache is reported by about one third of patients using dipyridamole (DP) after stroke or TIA." | 5.11 | Dipyridamole and headache--a pilot study of initial dose titration. ( Husted, S; Lindgren, A; Staaf, G; Ziegler, B, 2004) |
| " From 1974 to 1986 we treated 20 symptomatic ET patients with microvascular circulation disturbances including erythromelalgia (N = 18), atypical or typical transient ischemic attacks (N = 6), or acute coronary ischemic syndrome (N = 3) with aspirin and one course of busulfan." | 5.09 | Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia. ( Michiels, JJ, 1999) |
| " We sought to determine whether clopidogrel compared with aspirin decreases the need for rehospitalization for ischemia and bleeding." | 5.09 | Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000) |
| " Although a 150 mg dose of aspirin reduced urinary dinor-TxB2 levels by over 75 per cent, it had no effect on the course of the chronic recurrent form of angina pectoris due to vasospasm ("vasotonic angina")." | 5.05 | Thromboxane A2 in vasotonic angina pectoris: evidence from direct measurements and inhibitor trials. ( FitzGerald, GA; Friesinger, GC; Maas, RL; Oates, JA; Roberts, LJ; Robertson, D; Robertson, RM, 1981) |
| "Dual antiplatelet therapy of clopidogrel added aspirin is an established treatment strategy to prevent recurrent ischemic event occurrence in coronary artery disease patients." | 4.89 | Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring. ( Gurbel, PA; Tantry, US, 2013) |
| "In those who have already survived myocardial infarction (MI) or stroke, or have had a transient ischaemic episode (TIA), daily low dose aspirin (ASA) reduces the risk of recurrences by an amount that greatly exceeds the risk of serious bleeding (secondary prevention)." | 4.88 | Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents. ( Meade, T, 2012) |
| "PubMed and MEDLINE searches (up to January 2010) were performed to identify primary literature, using search terms including aspirin, stroke prevention, acute ischemic stroke, acetylsalicylic acid, atrial fibrillation, myocardial infarction, and carotid endarterectomy." | 4.86 | Aspirin dosing for the prevention and treatment of ischemic stroke: an indication-specific review of the literature. ( Ansara, AJ; Arif, SA; Koehler, JM; Nisly, SA; Nordmeyer, ST, 2010) |
| "Patients with acute coronary syndromes and patients who undergo coronary stent implantation frequently receive dual antiplatelet therapy with aspirin and a thienopyridine." | 4.85 | Monitoring platelet function to reduce the risk of ischemic and bleeding complications. ( Price, MJ, 2009) |
| "To review the rationale, clinical practice guideline recommendations, and clinical trial data describing bleeding and clinical outcomes associated with the use of the combination of aspirin, a thienopyridine, and warfarin." | 4.84 | Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous? ( Hermosillo, AJ; Spinler, SA, 2008) |
| " Among the key recommendations in this chapter are the following: For patients with chronic limb ischemia, we recommend lifelong aspirin therapy in comparison to no antiplatelet therapy in patients with clinically manifest coronary or cerebrovascular disease (Grade 1A) and in those without clinically manifest coronary or cerebrovascular disease (Grade 1C+)." | 4.82 | Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. ( Clagett, GP; Jackson, MR; Lip, GY; Sobel, M; Tangelder, M; Verhaeghe, R, 2004) |
| "In the secondary prevention of cardiovascular, cerebrovascular, and ischemic events, the evidence supports that the benefits of aspirin treatment significantly outweigh the risk of a major hemorrhage." | 4.82 | Risk of hemorrhagic stroke with aspirin use: an update. ( Gorelick, PB; Weisman, SM, 2005) |
| "In patients with ACS who were free from ischemic or major bleeding events during the first 3 months after PCI, the subsequent clopidogrel treatment might reduce minor bleeding events without increasing the risk of MACCE compared with ticagrelor." | 4.31 | Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China. ( Li, X; Lin, Y; Peng, W; Zhang, Y, 2023) |
| " At 25 min of ischemia, animals received intravenous aspirin (20 mg/kg) or vehicle." | 4.31 | Aspirin Blocks the Infarct-Size Limiting Effect of Ischemic Postconditioning in the Rat. ( Birnbaum, Y; Ye, R; Ye, Y, 2023) |
| "The goal of this work was to investigate the short-term time-course benefit and risk of ticagrelor with aspirin in acute mild-moderate ischemic stroke or high-risk TIA in The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and ASA for Prevention of Stroke and Death (THALES) trial." | 4.12 | Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack. ( Amarenco, P; Denison, H; Evans, SR; Himmelmann, A; James, S; Johnston, SC; Knutsson, M; Ladenvall, P; Li, H; Molina, CA; Pan, Y; Wang, Y, 2022) |
| " This study aims to compare the impact of aspirin (ASA) monotherapy, P2Y12 monotherapy, and DAPT on limb salvage (LS), amputation-free survival (AFS), and overall survival (OS) in patients undergoing lower extremity peripheral endovascular intervention (PVI) for chronic limb-threatening ischemia (CLTI)." | 4.12 | P2Y12 inhibitor monotherapy is associated with superior outcomes as compared with aspirin monotherapy in chronic limb-threatening ischemia. ( Dosluoglu, HH; Dryjski, ML; Fakhoury, E; Harris, LM; Khan, SZ; Montross, B; O'Brien-Irr, MS; Rivero, M, 2022) |
| "Fatal AEs related to rivaroxaban combined with aspirin, including bleeding and ischemic events, have been reported mostly in the elderly, and sometimes involved medication errors." | 4.12 | Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from VigiBase. ( Ding, Q; Yan, S; Yue, QY; Zhang, Q, 2022) |
| "In AUGUSTUS (Open-Label, 2×2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention), patients with atrial fibrillation and a recent acute coronary syndrome and those undergoing percutaneous coronary intervention had less bleeding with apixaban than vitamin K antagonist (VKA) and with placebo than aspirin." | 3.96 | Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. ( Alexander, JH; Aronson, R; Goodman, SG; Granger, CB; Lopes, RD; Mehran, R; Thomas, L; Vora, AN; Windecker, S; Wojdyla, D, 2020) |
| "Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial." | 3.96 | Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. ( Bikdeli, B; Cho, J; Gupta, A; Hripcsak, G; Kim, J; Krumholz, HM; Londhe, A; Madigan, D; Park, J; Park, RW; Reich, CG; Rho, Y; Ryan, PB; Schuemie, M; Siapos, A; Suchard, MA; Weaver, J; You, SC, 2020) |
| "The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial found clinical benefit of low-dose rivaroxaban plus aspirin, but at the expense of increased bleeding risk in patients with stable vascular disease." | 3.91 | Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients. ( Abtan, J; Bhatt, DL; Darmon, A; Ducrocq, G; Elbez, Y; Montalescot, G; Ohman, EM; Popovic, B; Röther, J; Sorbets, E; Steg, PG; Wilson, PF; Zeymer, U, 2019) |
| "The goal of this study is to establish the prevalence of high on-treatment platelet reactivity to aspirin (HPRA) and clopidogrel (HPRC) in patients with critical limb ischemia (CLI)." | 3.88 | Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia. ( Al-Asady, N; Caro, J; Clavijo, LC; Dhillon, A; Matthews, RV; Rowe, V; Shavelle, DM; Tun, H, 2018) |
| "Background Dual antithrombotic therapy comprising a vitamin K antagonist (VKA) plus clopidogrel reduces the incidence of major bleeding compared with triple therapy (VKA + clopidogrel + aspirin) in acute coronary syndrome (ACS) patients with atrial fibrillation (AF), with a similar thrombotic risk." | 3.88 | Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation. ( Bonello, L; Camoin-Jau, L; Gaubert, M; Laine, M; Paganelli, F; Resseguier, N, 2018) |
| " Conservative treatment included: (a) weight-adjusted bemiparin plus six hours/day intravenous iloprost for 28 days, (b) aspirin (100 mg/day) plus cilostazol (100 mg twice/day) after discharge, and (c) strict recommendations/monitoring for smoking cessation." | 3.85 | Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia. ( Anastasiadou, C; Galyfos, G; Geropapas, G; Giannakakis, S; Kastrisios, G; Kerasidis, S; Maltezos, C; Papacharalampous, G; Papapetrou, A; Sachmpazidis, I, 2017) |
| "BACKGROUND To investigate the combination of beraprost sodium (BPS) and aspirin in the treatment of acute ischemic stroke (AIS)." | 3.85 | Beneficial Effect of Beraprost Sodium Plus Aspirin in the Treatment of Acute Ischemic Stroke. ( Chen, S; Chen, W; He, W; Li, S; Wei, D; Xie, S, 2017) |
| " MIAs were frequently preceded or followed by ocular ischemic events of blurred vision, scotomas, transient flashing of the eyes, and sudden transient partial blindness preceded or followed erythromelalgia in the toes or fingers." | 3.81 | Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera. ( Berneman, Z; De Raeve, H; Gadisseur, A; Lam, KH; Michiels, JJ; Schroyens, W, 2015) |
| "National practice guidelines recommend early aspirin administration to reduce mortality in acute coronary syndrome (ACS)." | 3.81 | Prehospital aspirin administration for acute coronary syndrome (ACS) in the USA: an EMS quality assessment using the NEMSIS 2011 database. ( Govindarajan, P; Mercer, MP; Tataris, KL, 2015) |
| "This study was conducted to determine whether there is additive benefit of dual-antiplatelet therapy (DAPT) with aspirin (acetylsalicylic acid [ASA]) and clopidogrel compared with ASA monotherapy among patients with symptomatic peripheral arterial disease." | 3.81 | Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease. ( Amsterdam, EA; Anderson, DR; Armstrong, EJ; Bang, H; Freischlag, JA; Laird, JR; Singh, GD; Yeo, KK, 2015) |
| " Patients with critical limb ischemia following stent thrombosis were included if dual antiplatelet therapy consisting of 100 mg aspirin and 75 mg clopidogrel per day had been administered over three months prior to enrollment." | 3.80 | Response to dual antiplatelet therapy in patients with peripheral artery occlusive disease suffering from critical limb ischemia. ( Baecker, C; Baro, D; Meybohm, P; Mutlak, H; Schmitz-Rixen, T; Wand, S; Weber, CF; Zacharowski, K, 2014) |
| " Here, we evaluated the influence of aspirin and etodolac, a selective cyclooxygenase-2 inhibitor, on neovascularization using a murine ischemia hind limb model." | 3.76 | The cyclooxygenase-2 selective inhibitor, etodolac, but not aspirin reduces neovascularization in a murine ischemic hind limb model. ( Hisatome, I; Kita, Y; Shimizu, T; Tanaka, K; Tsujimoto, S; Uozumi, N; Yamamoto, Y; Yoshida, A, 2010) |
| "We studied 137 patients undergoing antiplatelet therapy with clopidogrel and 336 patients with aspirin for the occurrence of neurological events (ischemic stroke and/or carotid revascularization)." | 3.73 | Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. ( Amighi, J; Brunner, M; Exner, M; Felber, K; Funk, M; Mannhalter, C; Minar, E; Mlekusch, W; Müller, M; Sabeti, S; Schillinger, M; Ziegler, S, 2005) |
| "The aim of the present study was to investigate the effects of the oxygen-carrying hemoglobin solution DCLHb (diaspirin-crosslinked hemoglobin) on microvascular perfusion and tissue oxygenation in striated skin muscle after the induction of critical ischemia followed by reperfusion." | 3.72 | [Oxygen-carrying solutions improve tissue oxygenation in striated skin muscle subjected to critical ischemia]. ( Hölzle, F; Nolte, D; Pickelmann, S; Swaid, S; Wolff, KD, 2003) |
| "Aspirin was not a significant factor in preventing graft failure or vascular death in patients undergoing bypass for critical limb ischemia." | 3.72 | The efficacy of aspirin in patients undergoing infra-inguinal bypass and identification of high risk patients. ( Edwards, AT; Mahmood, A; Simms, MH; Sintler, M; Smith, SR; Vohra, RK, 2003) |
| "Deep vein thrombosis (DVT) remains common in patients with acute ischemic stroke (AIS) receiving aspirin and graded compression stockings (considered standard thromboprophylaxis in the UK), most events occurring in patients with Barthel indices (BI) of <9 ('severe stroke') around the time of admission." | 3.72 | Screening for proximal deep vein thrombosis after acute ischemic stroke: a prospective study using clinical factors and plasma D-dimers. ( Coshall, C; Hunt, BJ; Kelly, J; Lewis, RR; Moody, A; Parmar, K; Rudd, A, 2004) |
| " We therefore examined the effect of lysine acetylsalicylate (L-ASA, 4-2000 microM) on neuronal function under normal conditions and following 1 h of ischemia using the in vitro rabbit retina preparation." | 3.70 | Acetylsalicylate administered during simulated ischemia reduces the recovery of neuronal function in the in vitro rabbit retina. ( Arango, PM; Chen, D; Maynard, KI; Ogilvy, CS, 1998) |
| "To assess the relationship of aspirin use and ischemic cranial nerve palsies among patients with diabetes mellitus and hypertension." | 3.70 | Aspirin use and the prevention of acute ischemic cranial nerve palsy. ( Cipollo, CL; Johnson, LN; Krohel, GB; Madsen, RW; Stetson, SW, 2000) |
| " Erythromelalgia is causally related to thrombocythaemia; prompt relief of painful symptoms after treatment with aspirin is typical." | 3.69 | [Cutaneous manifestations of essential thrombocythemia. Erythromelalgia, ischemic acrocyanosis, livedo racemosa]. ( Bauerschmitz, J; Knop, J, 1995) |
| "Aspirin, when compared to placebo and controls, significantly increased muscle interstitial oedema when given orally and intravenously." | 3.69 | Aspirin increases tissue oedema after skeletal muscle ischaemia and reperfusion. ( Braithwaite, BD; Earnshaw, JJ; Gelabert, H; Moore, WS; Petrik, PV; Pollen, DN; Quinones-Baldrich, WJ, 1996) |
| "This study was performed to determine the relationship between net ion fluxes across the rat gastric mucosa and gastric mucosal damage after gastric ischemia and after intravenous administration of acetylsalicylic acid, and to determine the effect of cimetidine on these parameters." | 3.67 | Effect of cimetidine on net ion fluxes across the rat gastric mucosa during mucosal damage after gastric ischemia and after intravenous acetylsalicylic acid. ( Parsons, ME; Pipkin, G; Price, CA, 1984) |
| "Thirty-five patients with gangrene or pregangrene of the feed associated with palpable peripheral pulses have been treated with the platelet suppressive drugs aspirin and dipyridamole." | 3.66 | Gangrene of the toes with palpable peripheral pulses. ( Chatterjee, DK; Greaney, M; Morris-Jones, W; Preston, FE, 1981) |
| "Twenty patients with ≥50 % angiographic stenosis of the SFA had blood drawn just proximal to the lesion and from a contralateral site free of disease." | 2.78 | Increased local cytokine production at culprit superficial femoral artery plaques. ( Adams, JE; Ashikaga, T; Bertges, DJ; Dauerman, HL; Donaldson, CW; Elgharib, NZ; Mueller, EL; Prabhu, W; Schneider, DJ, 2013) |
| " In this study, we investigated the effects of iloprost infusion on urinary 11-dehydro-TXB₂ and 8-iso-PGF(₂α) excretion rate, as in vivo indexes of thromboxane-dependent platelet activation and lipid peroxidation, respectively, and on platelet-derived proinflammatory sCD40L and nitric oxide bioavailability in 44 patients with CLI while on chronic treatment with low-dose aspirin." | 2.76 | Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost. ( Cuccurullo, C; Davì, G; Di Iorio, P; Di Michele, D; Di Ruscio, P; Ferrante, E; Lattanzio, S; Laurora, G; Lessiani, G; Liani, R; Sgrò, G; Simeone, E; Vazzana, N, 2011) |
| "The primary outcome was restenosis documented by magnetic resonance (MR) angiography or duplex imaging at 12 months." | 2.76 | Batroxobin plus aspirin reduces restenosis after angioplasty for arterial occlusive disease in diabetic patients with lower-limb ischemia. ( Cheng, YS; Li, MH; Liu, F; Tan, HQ; Wang, J; Wang, JB; Zhao, JG; Zhu, YQ, 2011) |
| "Major bleeding was associated with a 3-fold increased risk of subsequent ischemic events (crude hazard ratio, 3." | 2.74 | Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. ( Algra, A; Eikelboom, BC; Lawson, JA; Moll, FL; Tangelder, MJ; van Hattum, ES, 2009) |
| "Patients with lower extremity peripheral artery disease (PAD) are at increased risk of major adverse limb events (MALE)." | 2.72 | The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials. ( Costa, G; Gonçalves, L; Teixeira, R, 2021) |
| "Aspirin therapy was associated with a 48 percent reduction in the incidence of myocardial infarction (2." | 2.70 | Aspirin and mortality from coronary bypass surgery. ( Mangano, DT, 2002) |
| "152 patients with thromboangiitis obliterans (Buerger's disease) and pain from critical leg ischaemia were randomly allocated to receive iloprost, a chemically stable prostacyclin analogue, or low-dose aspirin, for 28 days in a double-blind trial." | 2.67 | Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO Study. ( Fiessinger, JN; Schäfer, M, 1990) |
| "The effect of 7-mono-hydroxyethylrutoside and its combination with acetylsalicylic acid was evaluated in a controlled clinical trial, performed in 105 patients with obliterative atherosclerosis of the lower limbs, and using non-invasive measurement of peripheral haemodynamic parameters--blood flow during reactive hyperaemia and ankle systolic blood pressure." | 2.66 | The effect of hydroxyethylrutoside and its combination with acetylsalicylic acid in patients with obliterative atherosclerosis. ( Linhart, J; Oliva, I; Prerovský, I; Roztocil, K, 1989) |
| "Preeclampsia, intrauterine growth restriction (IUGR), and placental abruption are obstetrical conditions that constitute the syndrome of ischemic placental disease or IPD, the leading cause of indicated preterm birth and an important cause of neonatal morbidity and mortality." | 2.50 | Prediction and prevention of ischemic placental disease. ( Cleary, KL; Friedman, AM, 2014) |
| "In the peripheral arteries, a thrombus superimposed on atherosclerosis contributes to the progression of peripheral artery disease (PAD), producing intermittent claudication (IC), ischemic necrosis, and, potentially, loss of the limb." | 2.50 | Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. ( Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E, 2014) |
| " Currently available antiplatelet drugs have some limitations which might be overcomed by improved dosing regimens, use of combination of agents affecting different platelet functions and, in particular, by the new antiplatelet drugs (new arterial antithrombotics) with distinct pharmacodynamic properties offering new advantages, including faster onset of action, greater potency, and reversibility of effects." | 2.49 | [Present and future of pharmaco-arteriothromboprophylaxis in clinical practice. Guidelines of Angiology Section of Slovak Medical Chamber]. ( Dukát, A; Gašpar, L; Gavornik, P, 2013) |
| "Fundamentally, acute coronary syndromes are platelet-centric diseases, resulting from platelet-rich thrombi that develop at the site of vessel wall injury." | 2.44 | The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome. ( Gurbel, PA; Tantry, US, 2008) |
| "Atherothrombosis is a generalized and progressive process with an inflammatory component." | 2.44 | Role of antiplatelet agents in the primary and secondary prevention of atherothrombotic events in high risk-patients. ( Ellahham, S, 2008) |
| " Furthermore, (i) the optimal dosage of aspirin for complete inhibition of platelet aggregation by physiological agonists (i." | 2.43 | Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance. ( Christiaens, L; Macchi, L; Sorel, N, 2006) |
| "Hypertension that complicates preeclampsia in pregnancy is a disorder that requires special consideration in both prevention and pharmacologic treatment." | 2.43 | Pathophysiology and medical management of systemic hypertension in preeclampsia. ( Frishman, WH; Schlocker, SJ; Tejani, N; Veresh, M, 2006) |
| "In children and young adults, amaurosis fugax is a benign condition." | 2.38 | Atherosclerotic carotid disease and the eye. ( Breen, LA, 1991) |
| " Long term use of these drugs may prevent deterioration in those patients with progressive disease, and controlled trials on this aspect of treatment are now required." | 2.36 | Can drugs help patients with lower limb ischaemia? ( Bell, PR; Boobis, LH, 1982) |
| "A 50-year-old woman with a history of Crohn's disease treated with adalimumab presented with left hand pain and duskiness." | 1.56 | Digital ischaemia secondary to adalimumab-induced antiphospholipid syndrome. ( Cheemalavagu, S; Knight, JS; McCoy, SS, 2020) |
| "Aspirin was prescribed in 99." | 1.56 | Baseline clinical characteristics and patient profile of the TURKMI registry: Results of a nation-wide acute myocardial infarction registry in Turkey. ( Akboğa, M; Aktaş, I; Aladağ, N; Arın, CB; Asoğlu, R; Deveci, OS; Doğan, A; Dural, M; Erol, MK; Güneş, Y; Ince, O; Kayıkçıoğlu, M; Kılıçkap, M; Kurt, IH; Örnek, E; Özkan, E; Şen, T; Sinan, ÜY; Somuncu, MU; Tüner, H; Yenerçağ, M; Zeybey, U, 2020) |
| "For patients with thromboangiitis obliterans (TAO), revascularization with bypass or angioplasty is frequently not feasible due to the poor outflow of the distal small vessels." | 1.48 | Autologous bone marrow-derived mononuclear cell therapy in Chinese patients with critical limb ischemia due to thromboangiitis obliterans: 10-year results. ( Cui, S; Dardik, A; Gu, Y; Guo, J; Guo, L; Tong, Z, 2018) |
| "56%) was the most common triple Western medicine therapy, often combined with antibiotics and blood stasis drugs in use." | 1.46 | [Drug combination characteristics of Shenxiong glucose injection in treating ischemic cerebrovascular disease in real world]. ( Jia, PP; Liu, H; Wang, GQ; Xie, YM; Zhang, Y; Zhuang, Y, 2017) |
| "Atorvastatin 80 mg was found to be independent predictor of survival, and major amputation was found to be independent predictor of mortality." | 1.39 | Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry). ( Buszman, PE; Buszman, PP; Kiesz, RS; Konkolewska, MD; Martin, JL; Radvany, MG; Szymanski, R; Wiernek, BK; Wiernek, SL, 2013) |
| "We compared patients undergoing PCI who received aspirin and clopidogrel loading dose in addition to either conventional bivalirudin dosing (intravenous [IV] bolus of 0." | 1.38 | Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study. ( Ghosn, S; Sheikh-Taha, M, 2012) |
| "The prognosis of traumatic dissection of the internal carotid artery is worse than for spontaneous dissections." | 1.33 | Endovascular stent-assisted angioplasty in the management of traumatic internal carotid artery dissections. ( Ben-Hur, T; Cohen, JE; Gomori, JM; Rajz, G; Umansky, F, 2005) |
| "We report a 1-month-old infant with Kawasaki disease and peripheral gangrene." | 1.33 | Infantile Kawasaki disease and peripheral gangrene. ( Durall, AL; Mullett, CJ; Phillips, JR; Weisse, ME, 2006) |
| "Aspirin was administered for vascular event prevention." | 1.32 | Aspirin withdrawal and acute lower limb ischemia. ( Albaladejo, P; Castier, Y; Francis, F; Geeraerts, T; Lesèche, G; Marty, J, 2004) |
| "During reactive hyperemia, plasma endothelin was reduced in normal subjects (-1." | 1.30 | Postischemic hyperemia in subjects with lower limbs obstructive arteriopathy: role of PGI2 and endothelin. ( Arosio, E; Lechi, A; Minuz, P; Pancera, P; Ribul, M; Rossi, L, 1997) |
| "Pregnancy was confirmed and therapy with platelet aggregation inhibitor was introduced." | 1.30 | Pregnancy in a patient with essential thrombocytosis. ( Appiano, G; Caremani, M; Lapini, L; Rossi, G, 1997) |
| "Indications for surgery included vertebrobasilar insufficiency (22." | 1.30 | Carotid-subclavian bypass for subclavian artery revascularization: long-term follow-up and effect of antiplatelet therapy. ( Dresler, C; Haverich, A; Wahlers, T; Wittwer, T, 1998) |
| "Method of complex surgical treatment of inguinal hernia in children, basing on the early conduction of surgical correction of pathology, application of microsurgical technique of the operation conduction, using of pharmacologic defense of hematotesticular barrier and medicinal therapy of the man sexual gland ischemia, was elaborated and substantiated." | 1.30 | [Substantiation of complex surgical treatment of inguinal hernia in children based on pathogenetic criteria]. ( Horbatiuk, OM, 1998) |
| "Treatment with aspirin and prednisone in one patient." | 1.29 | Anterior ischemic optic neuropathy secondary to interferon alfa. ( Purvin, VA, 1995) |
| "Heparin-associated thrombocytopenia is mediated through IgG or IgM immunoglobulin fractions and is believed to be an immune phenomenon, with heparin acting as a hapten." | 1.27 | Plasmapheresis in the management of heparin-associated thrombocytopenia with thrombosis. ( Nand, S; Robinson, JA, 1988) |
| "We assessed hyperalgesia, by measuring tail flick latency following tail immersion in water at 49 degrees C, immediately after releasing the tourniquet and then at 30 min intervals for 2 h." | 1.27 | Injectable aspirin and mepyramine abolish post-ischaemic hyperalgesia in rats. ( Butkow, N; Gelgor, L; Mitchell, D; Phillips, S, 1986) |
| "Aspirin tablets were placed in the stomach of anesthetized cats by gastrotomy." | 1.26 | Aspirin damage to ischemic gastric mucosa in shocked cats. ( Leiknes, KA; Svanes, K; Søreide, O; Varhaug, JE, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 43 (16.23) | 18.7374 |
| 1990's | 47 (17.74) | 18.2507 |
| 2000's | 72 (27.17) | 29.6817 |
| 2010's | 68 (25.66) | 24.3611 |
| 2020's | 35 (13.21) | 2.80 |
| Authors | Studies |
|---|---|
| Anand, SS | 7 |
| Hiatt, W | 1 |
| Dyal, L | 1 |
| Bauersachs, R | 1 |
| Berkowitz, SD | 6 |
| Branch, KRH | 1 |
| Debus, S | 3 |
| Fox, KAA | 1 |
| Liang, Y | 1 |
| Muehlhofer, E | 6 |
| Nehler, M | 3 |
| Haskell, LP | 6 |
| Patel, M | 1 |
| Szarek, M | 5 |
| Yusuf, S | 1 |
| Eikelboom, J | 1 |
| Bonaca, MP | 7 |
| Hess, CN | 4 |
| Debus, ES | 3 |
| Nehler, MR | 3 |
| Patel, MR | 5 |
| Capell, WH | 4 |
| Hsia, J | 1 |
| Beckman, JA | 1 |
| Brodmann, M | 2 |
| Diaz, R | 2 |
| Habertheuer, P | 1 |
| Leeper, NJ | 1 |
| Powell, RJ | 1 |
| Sillesen, H | 3 |
| Bauersachs, RM | 5 |
| Marcaccio, CL | 1 |
| Patel, PB | 1 |
| Wang, S | 1 |
| Rastogi, V | 1 |
| Moreira, CC | 1 |
| Siracuse, JJ | 1 |
| Schermerhorn, ML | 2 |
| Stangenberg, L | 1 |
| Welsh, RC | 2 |
| Dehghani, P | 1 |
| Lopes, R | 1 |
| Wojdyla, DM | 1 |
| Aronson, R | 2 |
| Granger, CB | 2 |
| Windecker, S | 2 |
| Vora, AN | 2 |
| Vinereanu, D | 1 |
| Halvorsen, S | 1 |
| Parkhomenko, A | 2 |
| Mehran, R | 2 |
| Alexander, JH | 2 |
| Goodman, S | 1 |
| McClure, GR | 1 |
| Kaplovitch, E | 1 |
| Chan, N | 1 |
| Rothweiler, R | 1 |
| Gerlach, V | 1 |
| Voss, P | 1 |
| Poxleitner, P | 1 |
| Ermer, M | 1 |
| Gross, C | 1 |
| Schwer, C | 1 |
| Vach, K | 1 |
| Kalbhenn, J | 1 |
| Metzger, M | 1 |
| Wang, Y | 2 |
| Pan, Y | 1 |
| Li, H | 1 |
| Amarenco, P | 1 |
| Denison, H | 1 |
| Evans, SR | 1 |
| Himmelmann, A | 1 |
| James, S | 2 |
| Knutsson, M | 1 |
| Ladenvall, P | 1 |
| Molina, CA | 1 |
| Johnston, SC | 3 |
| Lieder, HR | 1 |
| Tsoumani, M | 1 |
| Andreadou, I | 1 |
| Schrör, K | 1 |
| Heusch, G | 1 |
| Kleinbongard, P | 1 |
| Khan, SZ | 1 |
| O'Brien-Irr, MS | 1 |
| Fakhoury, E | 1 |
| Montross, B | 1 |
| Rivero, M | 1 |
| Dosluoglu, HH | 1 |
| Harris, LM | 1 |
| Dryjski, ML | 1 |
| Zhang, Q | 1 |
| Ding, Q | 1 |
| Yan, S | 1 |
| Yue, QY | 1 |
| Luu, JM | 1 |
| Wei, J | 1 |
| Shufelt, CL | 1 |
| Asif, A | 1 |
| Tjoe, B | 1 |
| Theriot, P | 1 |
| Bairey Merz, CN | 1 |
| Hayashi, N | 1 |
| Matsuyama, Y | 1 |
| Fujiwara, T | 1 |
| Peng, W | 3 |
| Zhang, Y | 4 |
| Li, X | 4 |
| Lin, Y | 3 |
| Govsyeyev, N | 2 |
| Conte, MS | 2 |
| Chung, J | 2 |
| Dorigo, W | 2 |
| Gudz, I | 3 |
| Krievins, D | 2 |
| Mills, J | 2 |
| Moll, F | 2 |
| Norgren, L | 2 |
| Piffaretti, G | 2 |
| Powell, R | 2 |
| Szalay, D | 2 |
| Wohlauer, M | 2 |
| Jaeger, N | 3 |
| Gorog, DA | 1 |
| Jeyalan, V | 1 |
| Markides, RIL | 1 |
| Navarese, EP | 1 |
| Jeong, YH | 1 |
| Farag, M | 1 |
| Li, Y | 1 |
| Lei, M | 1 |
| Yang, Y | 1 |
| An, L | 1 |
| Zhou, H | 1 |
| Wang, J | 2 |
| Zhao, Z | 2 |
| Wang, X | 2 |
| Nie, S | 1 |
| Hau, WK | 1 |
| Xue, Z | 1 |
| Tian, MY | 1 |
| Wang, XY | 1 |
| Chen, F | 1 |
| Guo, YF | 1 |
| De Luca, L | 1 |
| Saito, Y | 1 |
| Kobayashi, Y | 1 |
| Hari, G | 1 |
| Skeik, N | 1 |
| Cheemalavagu, S | 1 |
| McCoy, SS | 1 |
| Knight, JS | 1 |
| Hočevar, A | 2 |
| Ješe, R | 1 |
| Tomšič, M | 2 |
| Rotar, Ž | 1 |
| Espinola-Klein, C | 1 |
| Fanelli, F | 1 |
| Diao, L | 1 |
| Pap, AF | 1 |
| Kittelson, JM | 1 |
| Mátyás, L | 1 |
| Krievins, DK | 1 |
| Hiatt, WR | 1 |
| Wojdyla, D | 1 |
| Thomas, L | 1 |
| Goodman, SG | 1 |
| Lopes, RD | 2 |
| Erol, MK | 1 |
| Kayıkçıoğlu, M | 1 |
| Kılıçkap, M | 1 |
| Arın, CB | 1 |
| Kurt, IH | 1 |
| Aktaş, I | 1 |
| Güneş, Y | 1 |
| Özkan, E | 1 |
| Şen, T | 1 |
| Ince, O | 1 |
| Örnek, E | 1 |
| Asoğlu, R | 1 |
| Aladağ, N | 1 |
| Zeybey, U | 1 |
| Sinan, ÜY | 1 |
| Dural, M | 1 |
| Tüner, H | 1 |
| Doğan, A | 1 |
| Yenerçağ, M | 1 |
| Akboğa, M | 1 |
| Deveci, OS | 1 |
| Somuncu, MU | 1 |
| Biagioni, RB | 1 |
| Agati, LB | 1 |
| Sacilotto, R | 1 |
| Wolosker, N | 1 |
| Sobreira, ML | 1 |
| de Freitas Soares, BL | 1 |
| Joviliano, EE | 1 |
| Bernardi, WH | 1 |
| Junior, VC | 1 |
| Caffaro, RA | 1 |
| Fioranelli, A | 1 |
| Van Bellen, B | 1 |
| Casella, IB | 1 |
| Fidelis, RJR | 1 |
| Flumignan, RLG | 1 |
| Comerota, AJ | 1 |
| Ramacciotti, E | 1 |
| Lanthier, L | 1 |
| Huard, G | 1 |
| Plourde, ME | 1 |
| Cauchon, M | 1 |
| Florêncio, FKZ | 1 |
| Tenório, MO | 1 |
| Macedo Júnior, ARA | 1 |
| Lima, SG | 1 |
| You, SC | 1 |
| Rho, Y | 1 |
| Bikdeli, B | 1 |
| Kim, J | 1 |
| Siapos, A | 1 |
| Weaver, J | 1 |
| Londhe, A | 1 |
| Cho, J | 1 |
| Park, J | 1 |
| Schuemie, M | 1 |
| Suchard, MA | 1 |
| Madigan, D | 1 |
| Hripcsak, G | 1 |
| Gupta, A | 1 |
| Reich, CG | 1 |
| Ryan, PB | 1 |
| Park, RW | 1 |
| Krumholz, HM | 1 |
| Perdan Pirkmajer, K | 1 |
| Kramarič, J | 1 |
| Costa, G | 1 |
| Gonçalves, L | 1 |
| Teixeira, R | 1 |
| Lapébie, FX | 1 |
| Aboyans, V | 1 |
| Lacroix, P | 2 |
| Constans, J | 2 |
| Boulon, C | 1 |
| Messas, E | 1 |
| Ferrières, J | 1 |
| Bongard, V | 1 |
| Bura-Rivière, A | 1 |
| Birnbaum, Y | 1 |
| Ye, R | 1 |
| Ye, Y | 1 |
| Qiao, M | 1 |
| Bi, Q | 1 |
| Fu, P | 1 |
| Song, Z | 1 |
| Guo, F | 1 |
| Galyfos, G | 1 |
| Kerasidis, S | 1 |
| Kastrisios, G | 1 |
| Giannakakis, S | 1 |
| Sachmpazidis, I | 1 |
| Anastasiadou, C | 1 |
| Geropapas, G | 1 |
| Papapetrou, A | 1 |
| Papacharalampous, G | 1 |
| Maltezos, C | 1 |
| Wilson, RM | 1 |
| Elmaraghi, S | 1 |
| Rinker, BD | 1 |
| Chen, S | 1 |
| Xie, S | 1 |
| He, W | 1 |
| Wei, D | 1 |
| Li, S | 1 |
| Chen, W | 1 |
| Wang, GQ | 1 |
| Xie, YM | 1 |
| Liu, H | 1 |
| Jia, PP | 1 |
| Zhuang, Y | 1 |
| Hirono, J | 1 |
| Sanaki, H | 1 |
| Kitada, K | 1 |
| Sada, H | 1 |
| Suzuki, A | 1 |
| Lie, LK | 1 |
| Segi-Nishida, E | 1 |
| Nakagawa, K | 1 |
| Hasegawa, H | 1 |
| Clavijo, LC | 1 |
| Al-Asady, N | 1 |
| Dhillon, A | 1 |
| Matthews, RV | 1 |
| Caro, J | 1 |
| Tun, H | 1 |
| Rowe, V | 1 |
| Shavelle, DM | 1 |
| Gaubert, M | 1 |
| Resseguier, N | 1 |
| Laine, M | 1 |
| Bonello, L | 1 |
| Camoin-Jau, L | 1 |
| Paganelli, F | 1 |
| Bath, PM | 1 |
| Woodhouse, LJ | 1 |
| Appleton, JP | 1 |
| Beridze, M | 1 |
| Christensen, H | 1 |
| Dineen, RA | 1 |
| Duley, L | 1 |
| England, TJ | 1 |
| Flaherty, K | 1 |
| Havard, D | 1 |
| Heptinstall, S | 1 |
| James, M | 1 |
| Krishnan, K | 1 |
| Markus, HS | 1 |
| Montgomery, AA | 1 |
| Pocock, SJ | 1 |
| Randall, M | 1 |
| Ranta, A | 1 |
| Robinson, TG | 1 |
| Scutt, P | 1 |
| Venables, GS | 1 |
| Sprigg, N | 1 |
| Attal, R | 1 |
| Lazareth, I | 1 |
| Angelopoulos, G | 1 |
| Priollet, P | 2 |
| Guo, J | 1 |
| Guo, L | 1 |
| Cui, S | 1 |
| Tong, Z | 1 |
| Dardik, A | 1 |
| Gu, Y | 1 |
| Easton, JD | 2 |
| Farrant, M | 2 |
| Barsan, W | 1 |
| Conwit, RA | 1 |
| Elm, JJ | 2 |
| Kim, AS | 2 |
| Lindblad, AS | 2 |
| Palesch, YY | 2 |
| Lewis, SR | 1 |
| Pritchard, MW | 1 |
| Schofield-Robinson, OJ | 1 |
| Alderson, P | 1 |
| Smith, AF | 1 |
| Rise, N | 2 |
| Kristiansen, J | 2 |
| Hvas, AM | 2 |
| Grove, EL | 2 |
| Würtz, M | 2 |
| Neergaard-Petersen, S | 2 |
| Kristensen, SD | 2 |
| Povsic, TJ | 1 |
| Ohman, EM | 2 |
| Roe, MT | 1 |
| White, J | 1 |
| Rockhold, FW | 1 |
| Montalescot, G | 3 |
| Cornel, JH | 1 |
| Nicolau, JC | 2 |
| Steg, PG | 5 |
| Bode, C | 1 |
| Plotnikov, AN | 1 |
| Mundl, H | 1 |
| Gibson, CM | 1 |
| Barsan, WG | 1 |
| Zurita, KG | 1 |
| Albers, GW | 1 |
| Cucchiara, BL | 1 |
| Kleindorfer, DO | 1 |
| Lutsep, HL | 1 |
| Pearson, C | 1 |
| Sethi, P | 1 |
| Vora, N | 1 |
| Darmon, A | 1 |
| Sorbets, E | 1 |
| Ducrocq, G | 1 |
| Elbez, Y | 1 |
| Abtan, J | 1 |
| Popovic, B | 1 |
| Röther, J | 1 |
| Wilson, PF | 1 |
| Zeymer, U | 1 |
| Bhatt, DL | 6 |
| Gassman, AA | 1 |
| Degner, BC | 1 |
| Al-Nouri, O | 1 |
| Philippi, L | 1 |
| Hershberger, R | 1 |
| Halandras, P | 1 |
| Aulivola, B | 1 |
| Milner, R | 1 |
| Palladino, M | 1 |
| Gatto, I | 1 |
| Neri, V | 1 |
| Straino, S | 1 |
| Smith, RC | 1 |
| Silver, M | 1 |
| Gaetani, E | 1 |
| Marcantoni, M | 1 |
| Giarretta, I | 1 |
| Stigliano, E | 1 |
| Capogrossi, M | 1 |
| Hlatky, L | 1 |
| Landolfi, R | 1 |
| Pola, R | 1 |
| Gavornik, P | 1 |
| Dukát, A | 1 |
| Gašpar, L | 1 |
| Kayssi, A | 1 |
| Shaikh, F | 1 |
| Roche-Nagle, G | 1 |
| Brandao, LR | 1 |
| Williams, SA | 1 |
| Rubin, BB | 1 |
| Friedman, AM | 1 |
| Cleary, KL | 1 |
| Di Minno, G | 1 |
| Spadarella, G | 1 |
| Cafaro, G | 1 |
| Petitto, M | 1 |
| Lupoli, R | 1 |
| Di Minno, A | 1 |
| de Gaetano, G | 1 |
| Tremoli, E | 1 |
| Azarbal, A | 1 |
| Clavijo, L | 1 |
| Gaglia, MA | 1 |
| Michiels, JJ | 3 |
| Berneman, Z | 2 |
| Gadisseur, A | 1 |
| Lam, KH | 1 |
| De Raeve, H | 1 |
| Schroyens, W | 2 |
| Alosh, M | 1 |
| Huque, MF | 1 |
| Koch, GG | 1 |
| Wu, IC | 1 |
| Hsieh, HM | 1 |
| Wu, MT | 1 |
| Polzin, A | 2 |
| Schleicher, M | 1 |
| Seidel, H | 1 |
| Scharf, RE | 1 |
| Merx, MW | 1 |
| Kelm, M | 2 |
| Zeus, T | 2 |
| Wand, S | 1 |
| Baro, D | 1 |
| Baecker, C | 1 |
| Meybohm, P | 1 |
| Schmitz-Rixen, T | 1 |
| Zacharowski, K | 1 |
| Mutlak, H | 1 |
| Weber, CF | 1 |
| Tataris, KL | 1 |
| Mercer, MP | 1 |
| Govindarajan, P | 1 |
| Armstrong, EJ | 1 |
| Anderson, DR | 1 |
| Yeo, KK | 1 |
| Singh, GD | 1 |
| Bang, H | 1 |
| Amsterdam, EA | 1 |
| Freischlag, JA | 1 |
| Laird, JR | 1 |
| Wisman, PP | 1 |
| Teraa, M | 1 |
| de Borst, GJ | 1 |
| Verhaar, MC | 1 |
| Roest, M | 1 |
| Moll, FL | 3 |
| Afzal, S | 1 |
| Balzer, J | 1 |
| Rassaf, T | 1 |
| Misra, DP | 1 |
| Chowdhury, AC | 1 |
| Lal, H | 1 |
| Mohindra, N | 1 |
| Agarwal, V | 1 |
| Dake, MD | 1 |
| Ansel, GM | 1 |
| Jaff, MR | 1 |
| Ohki, T | 1 |
| Saxon, RR | 1 |
| Smouse, HB | 1 |
| Machan, LS | 1 |
| Snyder, SA | 1 |
| O'Leary, EE | 1 |
| Ragheb, AO | 1 |
| Zeller, T | 1 |
| Yeh, RW | 1 |
| Secemsky, EA | 1 |
| Kereiakes, DJ | 1 |
| Normand, SL | 1 |
| Gershlick, AH | 1 |
| Cohen, DJ | 1 |
| Spertus, JA | 1 |
| Cutlip, DE | 1 |
| Rinaldi, MJ | 1 |
| Camenzind, E | 1 |
| Wijns, W | 1 |
| Apruzzese, PK | 1 |
| Song, Y | 1 |
| Massaro, JM | 1 |
| Mauri, L | 1 |
| Storey, RF | 1 |
| Cohen, M | 1 |
| Kuder, J | 1 |
| Goodrich, E | 1 |
| López-Sendón, J | 1 |
| Dellborg, M | 1 |
| Dalby, A | 1 |
| Špinar, J | 1 |
| Aylward, P | 1 |
| Corbalán, R | 1 |
| Abola, MTB | 1 |
| Jensen, EC | 1 |
| Held, P | 1 |
| Braunwald, E | 1 |
| Sabatine, MS | 1 |
| Domanski, MJ | 1 |
| Hunt, RH | 1 |
| Sun, S | 1 |
| Mei, S | 1 |
| Ma, N | 1 |
| Miao, Z | 1 |
| Zhao, M | 1 |
| Peng, S | 1 |
| Soden, PA | 1 |
| Zettervall, SL | 1 |
| Ultee, KH | 1 |
| Landon, BE | 1 |
| O'Malley, AJ | 1 |
| Goodney, PP | 1 |
| DeMartino, RR | 1 |
| Arya, S | 1 |
| Doly, JS | 1 |
| Lorian, E | 1 |
| Desormais, I | 1 |
| Bura Rivière, A | 1 |
| Fichter, AM | 1 |
| Ritschl, LM | 1 |
| Robitzky, LK | 1 |
| Wagenpfeil, S | 1 |
| Mitchell, DA | 1 |
| Wolff, KD | 3 |
| Mücke, T | 1 |
| Thott, O | 1 |
| Granath, F | 1 |
| Malmstedt, J | 1 |
| Wahlgren, CM | 1 |
| Borg, FA | 1 |
| Salter, VL | 1 |
| Dasgupta, B | 1 |
| Zimmermann, N | 1 |
| Hohlfeld, T | 1 |
| Stammler, F | 1 |
| Grau, C | 1 |
| Eckstein, HH | 1 |
| Gurbel, PA | 3 |
| Tantry, US | 2 |
| Hanhart, J | 1 |
| Koskas, P | 1 |
| Obadia, M | 1 |
| Le Mer, Y | 1 |
| Sahel, JA | 1 |
| Paques, M | 1 |
| Berger, CT | 1 |
| Wolbers, M | 1 |
| Meyer, P | 1 |
| Daikeler, T | 1 |
| Hess, C | 1 |
| Price, MJ | 1 |
| Mohler, ER | 1 |
| Georgiadis, D | 1 |
| Arnold, M | 1 |
| von Buedingen, HC | 1 |
| Valko, P | 1 |
| Sarikaya, H | 1 |
| Rousson, V | 2 |
| Mattle, HP | 1 |
| Bousser, MG | 1 |
| Baumgartner, RW | 1 |
| Angiolillo, DJ | 1 |
| Suryadevara, S | 1 |
| Serebruany, V | 1 |
| Sabaeva, E | 1 |
| Booze, C | 1 |
| Atar, OD | 1 |
| Eisert, C | 1 |
| Hanley, D | 1 |
| Collet, JP | 2 |
| van Hattum, ES | 2 |
| Algra, A | 5 |
| Lawson, JA | 5 |
| Eikelboom, BC | 4 |
| Tangelder, MJ | 5 |
| Tanaka, K | 1 |
| Yamamoto, Y | 1 |
| Tsujimoto, S | 1 |
| Uozumi, N | 1 |
| Kita, Y | 1 |
| Yoshida, A | 1 |
| Shimizu, T | 1 |
| Hisatome, I | 1 |
| Tacke, J | 1 |
| Lindhoff-Last, E | 1 |
| Mousa, SA | 1 |
| Jeske, WP | 1 |
| Fareed, J | 1 |
| Ansara, AJ | 1 |
| Nisly, SA | 1 |
| Arif, SA | 1 |
| Koehler, JM | 1 |
| Nordmeyer, ST | 1 |
| Ueno, M | 1 |
| Burdess, A | 2 |
| Nimmo, AF | 2 |
| Garden, OJ | 2 |
| Murie, JA | 2 |
| Dawson, AR | 2 |
| Fox, KA | 2 |
| Newby, DE | 2 |
| Breet, NJ | 1 |
| VAN Werkum, JW | 1 |
| Bouman, HJ | 1 |
| Kelder, JC | 1 |
| Ten Berg, JM | 1 |
| Hackeng, CM | 1 |
| Lessiani, G | 1 |
| Vazzana, N | 1 |
| Cuccurullo, C | 1 |
| Di Michele, D | 1 |
| Laurora, G | 1 |
| Sgrò, G | 1 |
| Di Ruscio, P | 1 |
| Simeone, E | 1 |
| Di Iorio, P | 1 |
| Lattanzio, S | 1 |
| Liani, R | 1 |
| Ferrante, E | 1 |
| Davì, G | 2 |
| Dechartres, A | 1 |
| Albaladejo, P | 2 |
| Mantz, J | 1 |
| Samama, CM | 1 |
| Ravaud, P | 1 |
| Tubach, F | 1 |
| Morofuji, Y | 1 |
| So, G | 1 |
| Hiu, T | 1 |
| Kawakubo, J | 1 |
| Hayashi, K | 1 |
| Kitagawa, N | 1 |
| Morikawa, M | 1 |
| Suyama, K | 1 |
| Nagata, I | 1 |
| Zhu, YQ | 1 |
| Li, MH | 1 |
| Zhao, JG | 1 |
| Tan, HQ | 1 |
| Wang, JB | 1 |
| Liu, F | 1 |
| Cheng, YS | 1 |
| Zhang, HL | 1 |
| Chen, XB | 1 |
| Fan, ZY | 1 |
| Wu, J | 1 |
| van der Loo, B | 2 |
| Braun, J | 1 |
| Koppensteiner, R | 3 |
| Aw, D | 1 |
| Sharma, JC | 1 |
| Meves, SH | 1 |
| Overbeck, U | 1 |
| Endres, HG | 1 |
| Krogias, C | 1 |
| Neubauer, H | 1 |
| Cameron, SJ | 1 |
| Goulopoulou, S | 1 |
| Weil, BR | 1 |
| Kanaley, JA | 1 |
| Sheikh-Taha, M | 1 |
| Ghosn, S | 1 |
| Meade, T | 1 |
| Kiesz, RS | 1 |
| Wiernek, SL | 1 |
| Wiernek, BK | 1 |
| Radvany, MG | 1 |
| Buszman, PP | 1 |
| Szymanski, R | 1 |
| Konkolewska, MD | 1 |
| Martin, JL | 1 |
| Buszman, PE | 1 |
| Donaldson, CW | 1 |
| Schneider, DJ | 1 |
| Bertges, DJ | 1 |
| Adams, JE | 1 |
| Elgharib, NZ | 1 |
| Mueller, EL | 1 |
| Prabhu, W | 1 |
| Ashikaga, T | 1 |
| Dauerman, HL | 1 |
| Vieth, M | 2 |
| Müller, H | 1 |
| Stolte, M | 1 |
| Avegliano, G | 1 |
| Evangelista, A | 1 |
| Elorz, C | 1 |
| González-Alujas, T | 1 |
| García del Castillo, H | 1 |
| Soler-Soler, J | 1 |
| Kowalik, Z | 1 |
| Kucharski, A | 1 |
| Hobot, J | 1 |
| Mangano, DT | 1 |
| Emmerich, J | 2 |
| Nolte, D | 3 |
| Pickelmann, S | 2 |
| Swaid, S | 2 |
| Hölzle, F | 2 |
| Brzozowski, T | 1 |
| Konturek, P | 1 |
| Konturek, SJ | 1 |
| Kwiecień, S | 1 |
| Sliwowski, Z | 1 |
| Pajdo, R | 1 |
| Duda, A | 1 |
| Ptak, A | 1 |
| Hahn, EG | 1 |
| Ojanen, R | 1 |
| Kaukinen, L | 1 |
| Seppälä, E | 1 |
| Kaukinen, S | 1 |
| Vapaatalo, H | 1 |
| Colwell, JA | 1 |
| Nesto, RW | 1 |
| WILLIAMS, MW | 1 |
| WILLIAMS, CS | 1 |
| KARTCHNER, MJ | 1 |
| Mahmood, A | 1 |
| Sintler, M | 1 |
| Edwards, AT | 1 |
| Smith, SR | 1 |
| Simms, MH | 1 |
| Vohra, RK | 1 |
| Hankey, GJ | 1 |
| Eikelboom, JW | 1 |
| Rao, U | 1 |
| Weston, C | 1 |
| Hellmann, DB | 1 |
| Nesher, G | 1 |
| Berkun, Y | 1 |
| Mates, M | 1 |
| Baras, M | 1 |
| Rubinow, A | 1 |
| Sonnenblick, M | 1 |
| Panneton, JM | 1 |
| Hollier, LH | 1 |
| Hofer, JM | 1 |
| Geeraerts, T | 1 |
| Francis, F | 1 |
| Castier, Y | 1 |
| Lesèche, G | 1 |
| Marty, J | 1 |
| Lindgren, A | 1 |
| Husted, S | 1 |
| Staaf, G | 1 |
| Ziegler, B | 1 |
| Clagett, GP | 3 |
| Sobel, M | 1 |
| Jackson, MR | 2 |
| Lip, GY | 1 |
| Tangelder, M | 1 |
| Verhaeghe, R | 1 |
| Jones, L | 2 |
| Griffin, S | 1 |
| Palmer, S | 1 |
| Main, C | 1 |
| Orton, V | 1 |
| Sculpher, M | 1 |
| Sudlow, C | 1 |
| Henderson, R | 1 |
| Hawkins, N | 1 |
| Riemsma, R | 1 |
| Kelly, J | 1 |
| Rudd, A | 1 |
| Lewis, RR | 1 |
| Coshall, C | 1 |
| Parmar, K | 1 |
| Moody, A | 1 |
| Hunt, BJ | 1 |
| Cohen, JE | 1 |
| Ben-Hur, T | 1 |
| Rajz, G | 1 |
| Umansky, F | 1 |
| Gomori, JM | 1 |
| Ziegler, S | 1 |
| Schillinger, M | 1 |
| Funk, M | 1 |
| Felber, K | 1 |
| Exner, M | 1 |
| Mlekusch, W | 1 |
| Sabeti, S | 1 |
| Amighi, J | 1 |
| Minar, E | 2 |
| Brunner, M | 1 |
| Müller, M | 1 |
| Mannhalter, C | 1 |
| Kesting, MR | 1 |
| Loeffelbein, DJ | 1 |
| Ariesen, MJ | 1 |
| Grobbee, DE | 1 |
| Gorelick, PB | 1 |
| Weisman, SM | 1 |
| Miyasaka, Y | 1 |
| Barnes, ME | 1 |
| Gersh, BJ | 1 |
| Cha, SS | 1 |
| Seward, JB | 1 |
| Bailey, KR | 1 |
| Iwasaka, T | 1 |
| Tsang, TS | 1 |
| White, WB | 1 |
| Parke, AL | 1 |
| Macchi, L | 1 |
| Sorel, N | 1 |
| Christiaens, L | 1 |
| Lechat, P | 1 |
| Durall, AL | 1 |
| Phillips, JR | 1 |
| Weisse, ME | 1 |
| Mullett, CJ | 1 |
| Collins, P | 1 |
| Ford, I | 1 |
| Greaves, M | 1 |
| Macaulay, E | 1 |
| Brittenden, J | 1 |
| Llinas, RH | 1 |
| Heeg, B | 1 |
| van Gestel, A | 1 |
| Hout, Bv | 1 |
| Olsen, J | 1 |
| Haghfelt, TH | 1 |
| Frishman, WH | 1 |
| Veresh, M | 1 |
| Schlocker, SJ | 1 |
| Tejani, N | 1 |
| Koudstaal, PJ | 1 |
| Lindemans, J | 1 |
| Neumann, HA | 1 |
| van Vliet, HH | 1 |
| Spring, S | 1 |
| Amann-Vesti, BR | 1 |
| Meier, T | 1 |
| Pfammatter, T | 1 |
| Banyai, M | 1 |
| Cleanthis, M | 1 |
| Bhattacharya, V | 1 |
| Smout, J | 1 |
| Ashour, H | 1 |
| Stansby, G | 1 |
| Catalano, M | 1 |
| Born, G | 1 |
| Peto, R | 1 |
| Patel, D | 1 |
| Moonis, M | 1 |
| Domenig, CM | 1 |
| Aspalter, M | 1 |
| Umathum, M | 1 |
| Holzenbein, TJ | 1 |
| McLornan, D | 1 |
| McMullin, M | 1 |
| Ertem, K | 1 |
| Ellahham, S | 1 |
| Andreozzi, GM | 1 |
| Arosio, E | 2 |
| Martini, R | 1 |
| Verlato, F | 1 |
| Visonà, A | 1 |
| Hermosillo, AJ | 1 |
| Spinler, SA | 1 |
| Kirk, RM | 1 |
| Boobis, LH | 1 |
| Bell, PR | 1 |
| Pipkin, G | 1 |
| Price, CA | 1 |
| Parsons, ME | 1 |
| Liguori, J | 1 |
| Werres, R | 1 |
| Rothfeld, D | 1 |
| Webster, J | 1 |
| Lewis, PJ | 1 |
| MacDermot, J | 1 |
| Hensby, CN | 1 |
| Kohner, EM | 1 |
| Porta, M | 1 |
| Robertson, RM | 1 |
| Robertson, D | 1 |
| Roberts, LJ | 1 |
| Maas, RL | 1 |
| FitzGerald, GA | 2 |
| Friesinger, GC | 1 |
| Oates, JA | 1 |
| Mersereau, WA | 1 |
| Hinchey, EJ | 1 |
| Broomé, A | 1 |
| Davidsson, T | 1 |
| Eklöf, B | 1 |
| Hansson, L | 1 |
| Morris-Jones, W | 1 |
| Preston, FE | 1 |
| Greaney, M | 1 |
| Chatterjee, DK | 1 |
| Dormandy, JA | 1 |
| Salem, HH | 1 |
| van der Weyden, MB | 1 |
| Koutts, J | 1 |
| Firkin, BG | 1 |
| McGreevy, JM | 1 |
| Moody, FG | 1 |
| Braithwaite, BD | 2 |
| Yusuf, SW | 1 |
| Dawson, K | 1 |
| Berridge, DC | 1 |
| Davies, E | 1 |
| Bowyer, R | 1 |
| Treska, V | 1 |
| Earnshaw, JJ | 2 |
| Orlov, RS | 1 |
| Erofeev, NP | 1 |
| Pan, HL | 2 |
| Stahl, GL | 4 |
| Longhurst, JC | 5 |
| Pincemail, J | 1 |
| Detry, O | 1 |
| Philippart, C | 1 |
| Defraigne, JO | 1 |
| Franssen, C | 1 |
| Burhop, K | 1 |
| Deby, C | 1 |
| Meurisse, M | 1 |
| Lamy, M | 1 |
| Purvin, VA | 1 |
| Bauerschmitz, J | 1 |
| Knop, J | 1 |
| Johansen, K | 1 |
| Hansen, ST | 1 |
| Rendig, SV | 2 |
| Carretero, OA | 1 |
| Skaria, AM | 1 |
| Hauser, C | 1 |
| Bowes, MP | 1 |
| Burhop, KE | 1 |
| Zivin, JA | 1 |
| Hensler, MK | 1 |
| Madsen, PV | 1 |
| Ouriel, K | 1 |
| Shortell, CK | 1 |
| DeWeese, JA | 1 |
| Green, RM | 1 |
| Francis, CW | 1 |
| Azodo, MV | 1 |
| Gutierrez, OH | 1 |
| Manzione, JV | 1 |
| Cox, C | 1 |
| Marder, VJ | 1 |
| Homberg, M | 1 |
| Tschöpe, D | 1 |
| Greber, H | 1 |
| Hackländer, T | 1 |
| Schwippert, B | 1 |
| Gries, FA | 1 |
| Mödder, U | 1 |
| Sarin, S | 1 |
| Shami, SK | 1 |
| Cheatle, TR | 1 |
| Bearn, P | 1 |
| Scurr, JH | 1 |
| Coleridge Smith, PD | 1 |
| Petrik, PV | 1 |
| Moore, WS | 1 |
| Gelabert, H | 1 |
| Pollen, DN | 1 |
| Quinones-Baldrich, WJ | 1 |
| Evans, RE | 1 |
| Dillon, MJ | 1 |
| Alfaham, M | 1 |
| Pancera, P | 1 |
| Minuz, P | 1 |
| Rossi, L | 1 |
| Ribul, M | 1 |
| Lechi, A | 1 |
| Born, GV | 1 |
| Collins, R | 1 |
| Rossi, G | 1 |
| Appiano, G | 1 |
| Lapini, L | 1 |
| Caremani, M | 1 |
| Walker, M | 1 |
| Hulme, TA | 1 |
| Rippon, MG | 1 |
| Walmsley, RS | 1 |
| Gunnigle, S | 1 |
| Lewin, M | 1 |
| Winsey, S | 1 |
| Molina, C | 1 |
| Alvarez-Sabín, J | 1 |
| Abilleira, S | 1 |
| Codina, A | 1 |
| Wittwer, T | 1 |
| Wahlers, T | 1 |
| Dresler, C | 1 |
| Haverich, A | 1 |
| Maynard, KI | 1 |
| Arango, PM | 1 |
| Chen, D | 1 |
| Ogilvy, CS | 1 |
| Leiderer, R | 1 |
| Schütze, E | 1 |
| Messmer, K | 2 |
| Dippel, DW | 1 |
| Horbatiuk, OM | 1 |
| von Dobschuetz, E | 1 |
| Hoffmann, T | 1 |
| Engelschalk, C | 1 |
| D'Sa, S | 1 |
| Machin, SJ | 1 |
| Watson, HR | 1 |
| Belcher, G | 1 |
| Horrocks, M | 1 |
| Chahal, PS | 1 |
| Ferro, D | 1 |
| Basili, S | 1 |
| Roccaforte, S | 1 |
| Di Franco, M | 1 |
| Cipollone, F | 1 |
| Ciabattoni, G | 1 |
| Johnson, LN | 1 |
| Stetson, SW | 1 |
| Krohel, GB | 1 |
| Cipollo, CL | 1 |
| Madsen, RW | 1 |
| Serebruany, VL | 1 |
| Lowry, DR | 1 |
| Fuzailov, SY | 1 |
| Levine, DJ | 1 |
| O'Connor, CM | 1 |
| Kobza, II | 1 |
| Hirsch, AT | 2 |
| Ringleb, PA | 2 |
| Hacke, W | 2 |
| Topol, EJ | 2 |
| Chew, DP | 1 |
| Bergmann, SR | 1 |
| Hennekes, S | 1 |
| Gusak, VK | 1 |
| Shtutin, AA | 1 |
| Rodin, IuV | 1 |
| Il'iushchenko, SV | 1 |
| Iurchuk, AIu | 1 |
| Narumiya, S | 1 |
| Nurden, P | 1 |
| Ndoko, S | 1 |
| Nurden, AT | 1 |
| Johnson, WC | 1 |
| Williford, WO | 1 |
| Valentine, RJ | 1 |
| Pöhlmann, G | 1 |
| Bär, H | 1 |
| Siegmund, R | 1 |
| Eidner, G | 1 |
| Figulla, HR | 1 |
| Davenport, HW | 1 |
| Sogge, MR | 1 |
| Griffith, JL | 1 |
| Sinar, DR | 1 |
| Mayes, GR | 1 |
| Zinner, MJ | 1 |
| Turtinen, L | 1 |
| Gurll, NJ | 1 |
| Del Beccaro, EJ | 1 |
| Heggers, JP | 1 |
| Robson, MC | 1 |
| Parry, JW | 1 |
| Svanes, K | 1 |
| Leiknes, KA | 1 |
| Varhaug, JE | 1 |
| Søreide, O | 1 |
| Callis, M | 1 |
| Weiss, HJ | 2 |
| Guiraud, B | 1 |
| David, J | 1 |
| Géraud, G | 1 |
| Biermé, R | 1 |
| Rascol, A | 1 |
| Gotshall, RA | 1 |
| Harker, LA | 1 |
| Poulos, E | 1 |
| Kingham, JG | 1 |
| Whorwell, PJ | 1 |
| Loehry, CA | 1 |
| Ranke, C | 1 |
| Creutzig, A | 1 |
| Luska, G | 1 |
| Wagner, HH | 1 |
| Galanski, M | 1 |
| Frölich, JC | 1 |
| Avenarius, HJ | 1 |
| Hecker, H | 1 |
| Alexander, K | 1 |
| Halliwell, B | 1 |
| Fiessinger, JN | 1 |
| Schäfer, M | 1 |
| Hansen, LL | 1 |
| Wiek, J | 1 |
| Danisevskis, M | 1 |
| Schrader, W | 1 |
| Gruel, Y | 1 |
| Lermusiaux, P | 1 |
| Lang, M | 1 |
| Darnige, L | 1 |
| Rupin, A | 1 |
| Delahousse, B | 1 |
| Guilmot, JL | 1 |
| Leroy, J | 1 |
| Rotto, DM | 1 |
| Kaufman, MP | 1 |
| Gruss, JD | 1 |
| Hiemer, W | 1 |
| Kroiss, A | 1 |
| Geissler, C | 1 |
| Ahmadi, R | 1 |
| Stümpflen, A | 1 |
| Ehringer, H | 1 |
| Altmann, E | 1 |
| Spranger, C | 1 |
| Schweizer, J | 1 |
| Hoffmann, A | 1 |
| Schmidt, PK | 1 |
| McCollum, C | 1 |
| Kenchington, G | 1 |
| Alexander, C | 1 |
| Franks, PJ | 1 |
| Greenhalgh, RM | 1 |
| Breen, LA | 1 |
| Nand, S | 1 |
| Robinson, JA | 1 |
| Perrett, D | 1 |
| Watson, A | 1 |
| Rolston, D | 1 |
| Roztocil, K | 1 |
| Oliva, I | 1 |
| Prerovský, I | 1 |
| Linhart, J | 1 |
| Wiebers, DO | 1 |
| Swanson, JW | 1 |
| Cascino, TL | 1 |
| Whisnant, JP | 1 |
| Obara, A | 1 |
| Płachta, H | 1 |
| Maruszyński, M | 1 |
| Bober, S | 1 |
| Zero, E | 1 |
| Mason, J | 1 |
| Welsch, J | 1 |
| Torhorst, J | 1 |
| Gana, TJ | 1 |
| Huhlewych, R | 1 |
| Koo, J | 1 |
| Gelgor, L | 1 |
| Phillips, S | 1 |
| Butkow, N | 1 |
| Mitchell, D | 1 |
| Hayhurst, JW | 1 |
| O'Brien, BM | 1 |
| Ishida, H | 1 |
| Baxter, TJ | 1 |
| Greenway, CV | 1 |
| Murthy, VS | 1 |
| McAlhany, JC | 1 |
| Czaja, AJ | 1 |
| Villarreal, Y | 1 |
| Pruitt, BA | 1 |
| Bányász, T | 1 |
| Csikós, E | 1 |
| Sármán, P | 1 |
| Skillman, JJ | 1 |
| Silen, W | 1 |
| Kincaid-Smith, P | 1 |
| Saker, BM | 1 |
| McKenzie, IF | 1 |
| Muriden, KD | 1 |
| Anggård, E | 1 |
| Tudhope, GR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424] | Phase 3 | 27,395 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Int[NCT02415400] | Phase 4 | 4,614 participants (Actual) | Interventional | 2015-06-04 | Completed | ||
| An International, Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Thrombotic Vascular Events in Patients With Symptomatic Peripheral Artery Disease Un[NCT02504216] | Phase 3 | 6,564 participants (Actual) | Interventional | 2015-08-18 | Completed | ||
| Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in Subjects With Symptomatic Peripheral Artery Disease (PAD) Undergoing Infrapopliteal Endovascular Peripheral Revascularization Procedures in Patients With Critical Limb[NCT04229264] | Phase 3 | 200 participants (Anticipated) | Interventional | 2020-01-09 | Recruiting | ||
| Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029] | Phase 3 | 4,881 participants (Actual) | Interventional | 2010-05-28 | Terminated (stopped due to The trial was halted by the DSMB.) | ||
| Trial of PCSK9 Inhibition in Patients With Acute Stroke and Symptomatic Intracranial Atherosclerosis - a Prospective, Randomized, Open-label, Blinded End-point Study With High-resolution MR Vessel Wall Imaging[NCT05001984] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-08-01 | Recruiting | ||
| Early Intensive Medical Therapy for the Prevention of Early Neurological Deterioration in Branch Atheromatous Disease[NCT04824911] | Phase 2 | 424 participants (Anticipated) | Interventional | 2021-03-23 | Recruiting | ||
| Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)[NCT05995600] | Phase 4 | 400 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Genotype Guided Antiplatelet Therapy In Ischemic Stroke[NCT05763862] | 350 participants (Anticipated) | Interventional | 2023-04-24 | Recruiting | |||
| A REAl-life Study on Short-term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or Transient Ischemic Attack[NCT05476081] | 1,067 participants (Anticipated) | Observational [Patient Registry] | 2021-02-03 | Recruiting | |||
| A Randomized, Double-Blind, Double-Dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Subjects With Acute Coronary Syndrom[NCT02293395] | Phase 2 | 3,037 participants (Actual) | Interventional | 2015-04-20 | Completed | ||
| Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients With Chronic Coronary Syndromes[NCT04347200] | 2,000 participants (Anticipated) | Observational [Patient Registry] | 2015-01-15 | Recruiting | |||
| Allogeneic Mesenchymal Stromal Cells for Angiogenesis and Neovascularization in No-option Ischemic Limbs; A Double-blind, Randomized, Placebo-controlled Trial[NCT03042572] | Phase 2/Phase 3 | 60 participants (Anticipated) | Interventional | 2018-12-31 | Not yet recruiting | ||
| Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Patients With Chronic Critical Limb Ischemia: a Randomized, Placebo-controlled Clinical Trial[NCT00371371] | Phase 1/Phase 2 | 160 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| A Multicenter, Randomized, Controlled, Superiority Clinical Trial to Evaluate the Safety and Efficacy of Drug-eluting Peripheral Arterial Stent System（G-stream） in the Treatment of the Above-the-knee Femoropopliteal Artery Stenosis or Occlusion[NCT05780359] | 280 participants (Anticipated) | Interventional | 2022-05-27 | Recruiting | |||
| Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery[NCT00120406] | 474 participants (Actual) | Interventional | 2005-03-31 | Completed | |||
| Personalization of Long-Term Antiplatelet Therapy Using a Novel Combined Demographic/Pharmacogenomic Strategy - The RAPID EXTEND Randomized Study[NCT03729401] | Phase 4 | 390 participants (Anticipated) | Interventional | 2019-08-22 | Suspended (stopped due to Testing supplies unavailable.) | ||
| Randomized 2x2 Factorial Trial Comparing the Cre8 Amphilimus-sirolimus Eluting Stent vs. the Synergy Everolimus-eluting Stent and a Personalized vs. Standard Duration of Dual Antiplatelet Therapy in All-comers Patients Undergoing Percutaneous Coronary Int[NCT04135989] | Phase 4 | 2,106 participants (Anticipated) | Interventional | 2020-01-01 | Active, not recruiting | ||
| A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S[NCT00977938] | Phase 4 | 25,682 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myoca[NCT01225562] | Phase 3 | 21,379 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization[NCT03953547] | 88 participants (Actual) | Observational | 2018-01-01 | Completed | |||
| The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (GCA).[NCT00974883] | 880 participants (Actual) | Observational | 2010-06-30 | Completed | |||
| Prevalence of Low Response to Clopidogrel in Patients After Acute Ischemic Stroke.[NCT01843361] | 159 participants (Actual) | Observational | 2010-07-31 | Completed | |||
| Effect of Low Molecular Weight Heparin vs Unfractionated Heparin on Bleeding After Cardiac Surgery[NCT00420667] | 43 participants (Actual) | Interventional | 2004-11-30 | Completed | |||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| Ovine Graft (Omniflow II) Versus PTFE in Below Knee Arterial Reconstruction: A Prospective Randomized Multi Centre Study[NCT00845585] | 0 participants (Actual) | Interventional | 2009-01-31 | Withdrawn (stopped due to found not enough centers for recruitment) | |||
| Randomized, Monocentric and Multidisciplinary Study of the Effects of an Intensive Rehabilitation by Interval Training With Active Recovery in Peripheral Arterial Disease With Claudication[NCT01734603] | Phase 3 | 40 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423] | Phase 2 | 113 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Asymptomatic Cuff Tears: A Model for Pain Development - Part B[NCT00923858] | 495 participants (Actual) | Observational | 2005-07-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 313 |
| Rivaroxaban 5mg + Aspirin Placebo | 366 |
| Rivaroxaban Placebo + Aspirin 100mg | 378 |
Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 282 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 389 |
| Rivaroxaban 5mg + Aspirin Placebo | 453 |
| Rivaroxaban Placebo + Aspirin 100mg | 516 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 329 |
| Rivaroxaban 5mg + Aspirin Placebo | 397 |
| Rivaroxaban Placebo + Aspirin 100mg | 450 |
Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 379 |
| Rivaroxaban 5mg + Aspirin Placebo | 448 |
| Rivaroxaban Placebo + Aspirin 100mg | 496 |
Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 353 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 288 |
| Rivaroxaban 5mg + Aspirin Placebo | 255 |
| Rivaroxaban Placebo + Aspirin 100mg | 170 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 138 |
"Time to first occurrence during the time the participants were treated with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 24.66 |
| Vitamin K Antagonist | 35.79 |
"Time to first death or ischenic event during the 6-month treatment period with aspirin or placebo.~N is the number of participants treated with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with death or ischemic events in each treatment group during the 6-month treatment period.~Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Acetylsalicylic Acid Film Coated Tablet | 15.28 |
| Placebo Matching Acetylsalicylic Acid Film Coated Tablet | 17.73 |
"Time to first all-cause death or all-cause hospitalization during the during the 6-month treatment period with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 57.24 |
| Vitamin K Antagonist | 69.19 |
"Time to first all-cause death or all-cause hospitalization during the 6-month period of treatment with aspirin or placebo.~N is the number of participants treated with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Acetylsalicylic Acid Film Coated Tablet | 65.72 |
| Placebo Matching Acetylsalicylic Acid Film Coated Tablet | 60.56 |
"Time to first ISTH major or CRNM bleeding during the 6-month period of treatment with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with major or CRNM bleeding divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 24.66 |
| Vitamin K Antagonist | 35.79 |
"Time to first ISTH major or CRNM bleeding during the treatment period of 6 months with aspirin or placebo.~N is the number of participants with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Acetylsalicylic Acid Film Coated Tablet | 40.51 |
| Placebo Matching Acetylsalicylic Acid Film Coated Tablet | 21.03 |
"Time to first occurrence during the 6-month treatment period with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with death or ischemic events in each treatment group during the during the 6-month period of treatment.~Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 15.85 |
| Vitamin K Antagonist | 17.17 |
(NCT02504216)
Timeframe: For each participant, the first occurrence of the outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1188.48 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 321 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 297 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1062.48 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 584 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 655 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the composite efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1108.29 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 514 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 588 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the composite efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1085.13 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 614 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 679 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the composite efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1108.79 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 433 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 528 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1154.04 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 262 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 356 |
Venous thromboembolic events were reported by investigator only. (NCT02504216)
Timeframe: For each participant, the first occurrence of the outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1187.65 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 25 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 41 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean time in follow-up survival time until ECOD that date was 1109.76 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 508 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 584 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the primary safety outcome after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo).
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 62 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 44 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered (NCT02504216)
Timeframe: For each participant, the first occurrence of the type 3b and above bleeding events according to the BARC classification after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo)
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 93 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 73 |
Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the major bleeding events according to the ISTH classification after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo).
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od | 140 |
| Rivaroxaban Placebo Bid + Aspirin 100 mg od | 100 |
Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 141 |
| Placebo | 167 |
Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 121 |
| Placebo | 160 |
Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 18 |
| Placebo | 12 |
Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 6 |
| Placebo | 4 |
Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 5 |
| Placebo | 3 |
Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 116 |
| Placebo | 156 |
Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 112 |
| Placebo | 155 |
Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 23 |
| Placebo | 10 |
Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 17 |
| Placebo | 7 |
Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 40 |
| Placebo | 13 |
Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 10 |
| Placebo | 7 |
Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 0 |
Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 2 |
Non CABG-related TIMI clinically significant bleeding events are sum of non CABG-related TIMI major bleeding events, TIMI minor bleeding events and TIMI bleeding events requiring medical attention. Major: any symptomatic intracranial bleeding: clinically overt signs of hemorrhage with hemoglobin (Hb) drop of greater than or equal to (>=)5 gram per deciliter (g/dl) (or absolute drop in hematocrit of >=15%) and fatal bleeding (results in death within 7 days); Minor: clinically overt sign of hemorrhage with Hb drop of 3 - <5 g/dl (or drop in hematocrit of 9 - <15%); requiring medical attention: bleeding event that required medical, surgical treatment/laboratory evaluation and did not meet criteria for major/minor bleeding event. (NCT02293395)
Timeframe: From start of study treatment until follow-up (up to 390 days)
| Intervention | participants (Number) |
|---|---|
| Rivaroxaban 2.5 mg Twice Daily (BID) | 80 |
| Acetylsalicylic Acid 100 mg Once Daily (OD) | 74 |
"Event-free survival is defined as freedom from the major adverse events of death, target lesion revascularization, target limb ischemia requiring surgical intervention (bypass or amputation of toe, foot or leg), surgical repair of the target vessel (e.g., dissection requiring surgery), and from worsening of the Rutherford classification by 2 classes or to class 5 or 6.~Participant flow is based on initial randomization of Zilver PTX or PTA (Percutaneous balloon angioplasty), and Event-free survival is based on Per-Protocol analysis where only patients who were treated according to their initial randomization are counted." (NCT00120406)
Timeframe: 12 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Zilver PTX | 90.4 |
| PTA (Control) | 83.9 |
Primary patency is defined as a Peak systolic velocity (PSV) ratio < 2.0 or angiographic percent diameter stenosis < 50%. (NCT00120406)
Timeframe: 12 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Zilver PTX | 82.7 |
| PTA (Control) | 32.7 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 1.70 |
| Propensity-matched BMS | 2.61 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.69 |
| DES 12-month DAPT | 1.45 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.40 |
| DES 12-month DAPT | 1.35 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.03 |
| BMS 12-month DAPT | 0.90 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.09 |
| BMS 12-month DAPT | 1.05 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.74 |
| DES 12-month DAPT | 1.88 |
The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.53 |
| DES 12-month DAPT | 1.57 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 11.37 |
| Propensity-matched BMS | 13.24 |
(NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.04 |
| BMS 12-month DAPT | 4.69 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.68 |
| BMS 12-month DAPT | 5.48 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 5.62 |
| DES 12-month DAPT | 6.49 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 4.34 |
| DES 12-month DAPT | 5.92 |
Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 5.1 |
| Ticagrelor 60 mg | 4.7 |
| Placebo | 5.2 |
A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of >= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug (NCT01225562)
Timeframe: First dosing up to 48 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.6 |
| Ticagrelor 60 mg | 2.3 |
| Placebo | 1.1 |
Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.9 |
| Ticagrelor 60 mg | 2.9 |
| Placebo | 3.4 |
Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 7.8 |
| Ticagrelor 60 mg | 7.8 |
| Placebo | 9.0 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 4 |
| Placebo | 5 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 1 |
| Placebo | 0 |
Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery
| Intervention | percentage (Number) |
|---|---|
| 75mg Clopidogrel | 94.3 |
| Placebo | 93.2 |
IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery
| Intervention | mm (Mean) |
|---|---|
| 75mg Clopidogrel | 4.1 |
| Placebo | 4.5 |
52 reviews available for aspirin and Ischemia
| Article | Year |
|---|---|
Antithrombotic Therapy in Peripheral Artery Disease: Risk Stratification and Clinical Decision Making.
Topics: Aspirin; Canada; Clinical Decision-Making; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhag | 2022 |
Comparison of De-escalation of DAPT Intensity or Duration in East Asian and Western Patients with ACS Undergoing PCI: A Systematic Review and Meta-analysis.
Topics: Acute Coronary Syndrome; Aspirin; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Ischemia; Percutan | 2023 |
Who may benefit from low-dose rivaroxaban plus aspirin? Practical implications for outpatients with cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Ischemia; | 2023 |
Update on Antithrombotic Therapy after Percutaneous Coronary Intervention.
Topics: Administration, Oral; Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; H | 2020 |
Digital ischemia in Behçet's disease: case-based review.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Aspirin; Azathioprine; Behcet Syndrome; Colchicine; | 2020 |
The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Aspirin; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemia; Lower Extremity; Periph | 2021 |
Continuation versus discontinuation of antiplatelet therapy for bleeding and ischaemic events in adults undergoing non-cardiac surgery.
Topics: Adult; Aspirin; Cause of Death; Clopidogrel; Elective Surgical Procedures; Hemorrhage; Humans; Ische | 2018 |
[Present and future of pharmaco-arteriothromboprophylaxis in clinical practice. Guidelines of Angiology Section of Slovak Medical Chamber].
Topics: Aspirin; Czech Republic; Drug Administration Schedule; Drug Therapy, Combination; Drugs, Investigati | 2013 |
Prediction and prevention of ischemic placental disease.
Topics: Abruptio Placentae; Anticoagulants; Ascorbic Acid; Aspirin; Calcium, Dietary; Dietary Supplements; F | 2014 |
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Int | 2014 |
Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: guidelines abound, but where are the data?
Topics: Aspirin; Cilostazol; Dipyridamole; Endovascular Procedures; Extremities; Humans; Ischemia; Periphera | 2015 |
Gangrene in Takayasu's arteritis: a report of two cases and review of literature.
Topics: Adolescent; Adrenal Cortex Hormones; Amputation, Surgical; Anticoagulants; Aspirin; Critical Illness | 2016 |
Neuro-ophthalmic complications in giant cell arteritis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Aspirin; Cytokines; Giant Cell Arteritis; Humans; | 2008 |
Clinical implications of aspirin resistance.
Topics: Aspirin; Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Resistance; | 2008 |
The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Blood Coagulation; Blood Platelets; Clopidogrel; Drug Therapy, Com | 2008 |
Monitoring platelet function to reduce the risk of ischemic and bleeding complications.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Hemo | 2009 |
Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Evidence-Based Me | 2009 |
Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus.
Topics: Aspirin; Clopidogrel; Diabetes Mellitus; Drug Resistance; Endothelium, Vascular; Humans; Ischemia; O | 2009 |
Platelet function testing and implications for clinical practice.
Topics: Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Hemorrhage; Hemostasis; Humans; Ischemia; Pl | 2009 |
[Medicinal therapy for interventional surgery of the peripheral vascular system].
Topics: Administration, Oral; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Drug Therap | 2010 |
Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase III as Topi | 2010 |
Aspirin dosing for the prevention and treatment of ischemic stroke: an indication-specific review of the literature.
Topics: Aspirin; Atherosclerosis; Carotid Artery Diseases; Dose-Response Relationship, Drug; Endothelium, Va | 2010 |
Antiplatelets in secondary stroke prevention: should clopidogrel be the first choice?
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Ischemia; Ischemic Attack, Transient; Platelet Aggregati | 2012 |
Primary prevention of ischaemic cardiovascular disorders with antiplatelet agents.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Ischemia; Myocardia | 2012 |
Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Cost Savings; Drug Monitoring; Drug Resistance; Drug | 2013 |
[Thrombosis and antithrombotic agents in peripheral artery disease].
Topics: Administration, Oral; Anticoagulants; Aspirin; Fibrinolytic Agents; Humans; Intermittent Claudicatio | 2002 |
The platelet in diabetes: focus on prevention of ischemic events.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Humans; | 2003 |
Antiplatelet agents in atherothrombotic diseases.
Topics: Arteriosclerosis; Aspirin; Clopidogrel; Dipyridamole; Humans; Ischemia; Platelet Aggregation Inhibit | 2004 |
Low-dose aspirin in the treatment of giant cell arteritis.
Topics: Aspirin; Blindness; Giant Cell Arteritis; Humans; Ischemia; Platelet Aggregation Inhibitors | 2004 |
Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Arterial Occlusive Diseases; Aspirin; Cilostazol; Clopidogrel; Contraindications; Evidence-Based Med | 2004 |
Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Delayed-Action Preparations; Diarrhea; Dipyridamole; Dr | 2004 |
Risk of hemorrhagic stroke with aspirin use: an update.
Topics: Adult; Aged; Aged, 80 and over; Angiography; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain | 2005 |
Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance.
Topics: Animals; Aspirin; Coronary Disease; Drug Resistance; Heart Failure; Humans; Ischemia; Platelet Aggre | 2006 |
[Prevention of major ischemic events in lower limb arterial disease: does aspirin play a role?].
Topics: Arterial Occlusive Diseases; Aspirin; Humans; Ischemia; Leg; Platelet Aggregation Inhibitors; Risk F | 2006 |
Pathophysiology and medical management of systemic hypertension in preeclampsia.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium; Calcium Channel Blockers; Cerebral Hemorrhage; Female | 2006 |
Clinical implications of aspirin resistance.
Topics: Aspirin; Cyclooxygenase 1; Drug Resistance; Enzyme Inhibitors; Heart Diseases; Humans; Ischemia; Pla | 2007 |
How would I manage a case of essential thrombocythaemia presenting with an ischaemic toe.
Topics: Aspirin; Evidence-Based Medicine; Humans; Hydroxyurea; Interferon-alpha; Ischemia; Janus Kinase 2; M | 2008 |
Role of antiplatelet agents in the primary and secondary prevention of atherothrombotic events in high risk-patients.
Topics: Aspirin; Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Dose-Response Relationship, Drug; D | 2008 |
Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Interactions; Drug Therapy, Com | 2008 |
Can drugs help patients with lower limb ischaemia?
Topics: Aged; Arteriosclerosis; Aspirin; Cholesterol; Collateral Circulation; Female; Hemodynamics; Humans; | 1982 |
[Acetylsalicylic acid treatment after peripheral vascular surgery].
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Humans; Ischemia; Leg; Postoperative Complications | 1994 |
When do vascular surgeons prescribe antiplatelet therapy? Current attitudes.
Topics: Angioplasty, Balloon; Arteriosclerosis; Aspirin; Dipyridamole; Graft Occlusion, Vascular; Humans; Is | 1993 |
The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Humans; Ischemia; Myocardial I | 1998 |
Adjuvant medical therapy in peripheral bypass surgery.
Topics: Alprostadil; Anticoagulants; Aspirin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dextrans; Do | 1999 |
Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery.
Topics: Administration, Oral; Amputation, Surgical; Anticoagulants; Aspirin; Graft Occlusion, Vascular; Huma | 1999 |
[The best of vascular pathology in 1999].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aortic Aneurysm; Aspirin; ATP-Binding Cassette Transporters | 2000 |
Genetic and pharmacological analysis of prostanoid receptor function.
Topics: Animals; Aspirin; Biological Transport; Bone Resorption; Cell Nucleus; Colonic Neoplasms; Cyclooxyge | 2001 |
[From the physiopathology of thrombosis to therapeutic targets].
Topics: Arteriosclerosis; Aspirin; Fibrinolytic Agents; Humans; Inflammation; Ischemia; Platelet Aggregation | 2001 |
Antiplatelet drugs-a new pharmacologic approach to the prevention of thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Brain; Clofibrate; Dextrans; Dipyridamole; Humans; Ischemi | 1976 |
Atherosclerotic carotid disease and the eye.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Blindness; Carotid Artery Diseas | 1991 |
Gastric mucosal barriers.
Topics: Animals; Aspirin; Atropine; Bile Acids and Salts; Cats; Diffusion; Dilatation; Ethanol; Gastric Acid | 1972 |
[Analgesic drugs for peroral use].
Topics: Analgesics; Arthritis, Rheumatoid; Aspirin; Headache; Humans; Ischemia; Kinetics; Neoplasms; Neuralg | 1970 |
53 trials available for aspirin and Ischemia
| Article | Year |
|---|---|
Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD.
Topics: Acute Disease; Aged; Aspirin; Female; Humans; Ischemia; Lower Extremity; Male; Middle Aged; Numbers | 2021 |
Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial.
Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Factor Xa Inhibitors; Female; Hemorrhage; Hum | 2022 |
Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD.
Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarc | 2022 |
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
Topics: Aspirin; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarction; Peripheral Arterial D | 2023 |
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
Topics: Aspirin; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarction; Peripheral Arterial D | 2023 |
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
Topics: Aspirin; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarction; Peripheral Arterial D | 2023 |
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
Topics: Aspirin; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarction; Peripheral Arterial D | 2023 |
Rivaroxaban in Peripheral Artery Disease after Revascularization.
Topics: Aged; Aspirin; Cardiovascular Diseases; Combined Modality Therapy; Double-Blind Method; Drug Therapy | 2020 |
Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial.
Topics: Angioplasty; Aspirin; Clopidogrel; Critical Illness; Factor Xa Inhibitors; Humans; Ischemia; Leg; Mu | 2020 |
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Clopidogrel; Denmark; Dipyridamole; Drug Therapy, Comb | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Administration Schedul | 2019 |
Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke.
Topics: Acute Disease; Aspirin; Clinical Protocols; Clopidogrel; Drug Therapy, Combination; Drug-Related Sid | 2019 |
Baseline Platelet Activation and Reactivity in Patients with Critical Limb Ischemia.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Case-Control Studies; Collagen; Female; Fibrinoge | 2015 |
Baseline Platelet Activation and Reactivity in Patients with Critical Limb Ischemia.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Case-Control Studies; Collagen; Female; Fibrinoge | 2015 |
Baseline Platelet Activation and Reactivity in Patients with Critical Limb Ischemia.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Case-Control Studies; Collagen; Female; Fibrinoge | 2015 |
Baseline Platelet Activation and Reactivity in Patients with Critical Limb Ischemia.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Case-Control Studies; Collagen; Female; Fibrinoge | 2015 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Aspirin; Diabetes Mellitus; Drug-Eluting Stent | 2016 |
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease.
Topics: Adenosine; Aged; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemor | 2016 |
Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis.
Topics: Aged; Asian People; Aspirin; Carboxylic Ester Hydrolases; Clopidogrel; Constriction, Pathologic; Cyt | 2016 |
Distribution of dipyridamole in blood components among post-stroke patients treated with extended release formulation.
Topics: Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Blood Platelets; Delayed-Action Preparations; | 2009 |
Bleeding increases the risk of ischemic events in patients with peripheral arterial disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cerebral Hemorrhage; Confide | 2009 |
Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia.
Topics: Aged; Amputation, Surgical; Aspirin; Clopidogrel; Double-Blind Method; Female; Flow Cytometry; Hemor | 2010 |
Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelets; CD40 Ligand; Chi-Square Distribution; | 2011 |
Batroxobin plus aspirin reduces restenosis after angioplasty for arterial occlusive disease in diabetic patients with lower-limb ischemia.
Topics: Aged; Analysis of Variance; Angioplasty; Arterial Occlusive Diseases; Aspirin; Batroxobin; China; Co | 2011 |
On-treatment function testing of platelets and long-term outcome of patients with peripheral arterial disease undergoing transluminal angioplasty.
Topics: Aged; Aged, 80 and over; Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspir | 2011 |
Regulation of blood flow by aspirin following muscle ischemia.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Aspirin; Body Composition; Cholest | 2012 |
Increased local cytokine production at culprit superficial femoral artery plaques.
Topics: Aspirin; CD40 Ligand; Clopidogrel; Constriction, Pathologic; Female; Femoral Artery; Humans; Hydroxy | 2013 |
Aspirin and mortality from coronary bypass surgery.
Topics: Aged; Antifibrinolytic Agents; Aspirin; Coronary Artery Bypass; Coronary Disease; Female; Humans; Is | 2002 |
Multicenter randomized prospective trial comparing a pre-cuffed polytetrafluoroethylene graft to a vein cuffed polytetrafluoroethylene graft for infragenicular arterial bypass.
Topics: Aged; Aged, 80 and over; Anastomosis, Surgical; Anticoagulants; Arterial Occlusive Diseases; Aspirin | 2004 |
Dipyridamole and headache--a pilot study of initial dose titration.
Topics: Aged; Aspirin; Dipyridamole; Drug Therapy, Combination; Female; Follow-Up Studies; Headache; Humans; | 2004 |
Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) Study.
Topics: Administration, Oral; Aged; Anticoagulants; Arteriosclerosis; Aspirin; Female; Fibrinolytic Agents; | 2005 |
Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial.
Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Dalteparin; Drug Therapy, Combinat | 2006 |
Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial.
Topics: Aged; Aspirin; Double-Blind Method; Female; Humans; Ischemia; Leg; Male; Peripheral Vascular Disease | 2007 |
Thromboxane A2 in vasotonic angina pectoris: evidence from direct measurements and inhibitor trials.
Topics: Adult; Angina Pectoris; Angina Pectoris, Variant; Arteries; Aspirin; Clinical Trials as Topic; Coron | 1981 |
A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia.
Topics: Acute Disease; Aged; Amputation, Surgical; Arm; Aspirin; Drug Therapy, Combination; Female; Humans; | 1994 |
Platelet inhibition with ASA/dipyridamole after percutaneous balloon angioplasty in patients with symptomatic lower limb arterial disease. A prospective double-blind trial. Study group on pharmacological treatment after PTA.
Topics: Aged; Angiography; Angioplasty, Balloon; Aspirin; Dipyridamole; Double-Blind Method; Drug Combinatio | 1994 |
The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Humans; Ischemia; Myocardial I | 1998 |
Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus.
Topics: Adult; Antibodies, Antiphospholipid; Antigens; Aspirin; Cross-Sectional Studies; Dose-Response Relat | 1999 |
Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Busulfan; Coronary Disease; Dise | 1999 |
Moderate alcohol consumption is associated with decreased platelet activity in patients presenting with acute myocardial infarction.
Topics: Aged; Alcohol Drinking; Aspirin; Cohort Studies; Enzyme-Linked Immunosorbent Assay; Ethanol; Female; | 2000 |
[The drug prevention of postoperative thromboses in patients with critical lower limb ischemia].
Topics: Anticoagulants; Aspirin; Critical Illness; Humans; Ischemia; Leg; Nadroparin; Platelet Aggregation I | 1999 |
Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators.
Topics: Aspirin; Brain Ischemia; Cause of Death; Clopidogrel; Confidence Intervals; Double-Blind Method; Fem | 2000 |
Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery.
Topics: Aspirin; Cardiac Surgical Procedures; Clopidogrel; Double-Blind Method; Female; Hospitalization; Hum | 2001 |
Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group.
Topics: Acenocoumarol; Adult; Aged; Aged, 80 and over; Aspirin; Blood Vessel Prosthesis Implantation; Female | 2001 |
[Application of preparation endotelon in complex treatment of chronic arterial insufficiency of lower extremities].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Arterial Occlusive Diseases; Aspirin; Biflavo | 2000 |
The effect of anticoagulation therapy and graft selection on the ischemic consequences of femoropopliteal bypass graft occlusion: results from a multicenter randomized clinical trial.
Topics: Aged; Amputation, Surgical; Anticoagulants; Aspirin; Boston; Femoral Vein; Fibrinolytic Agents; Foll | 2002 |
Proceedings: Prevention of ischemic cerebro vascular accident: a long term clinical trial with vasodilator and antiaggregating drugs.
Topics: Aspirin; Brain; Clinical Trials as Topic; Dihydroergotoxine; Dipyridamole; Ergoloid Mesylates; Human | 1975 |
[Comparison of 50 mg and 900 mg/day acetylsalicylic acid for prevention of recurrence after percutaneous transluminal angioplasty of the lower extremities: results of the LARA study].
Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Combined Modality Therapy; Dose-Re | 1992 |
Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO Study.
Topics: Adolescent; Adult; Amputation, Surgical; Anti-Arrhythmia Agents; Arm; Aspirin; Double-Blind Method; | 1990 |
[Isovolemic hemodilution on non-arteritic anterior optic neuropathy. Initial results of a randomized study].
Topics: Aged; Aspirin; Combined Modality Therapy; Female; Hemodilution; Humans; Hydroxyethyl Starch Derivati | 1991 |
[Experiences with adjuvant prostaglandin therapy in vascular surgery interventions].
Topics: Alprostadil; Arteriovenous Shunt, Surgical; Aspirin; Graft Occlusion, Vascular; Heparin; Humans; Isc | 1991 |
[Randomized comparative study of the recurrence rate following femoro-popliteal PTA: high (1.0 g/die) vs low (0.1 g/die) acetylsalicylic acid dose].
Topics: Angioplasty, Balloon; Aspirin; Combined Modality Therapy; Dose-Response Relationship, Drug; Femoral | 1991 |
PTFE or HUV for femoro-popliteal bypass: a multi-centre trial.
Topics: Arterial Occlusive Diseases; Aspirin; Bioprosthesis; Blood Vessel Prosthesis; Combined Modality Ther | 1991 |
The effect of hydroxyethylrutoside and its combination with acetylsalicylic acid in patients with obliterative atherosclerosis.
Topics: Adult; Analgesics; Anticoagulants; Arteriosclerosis Obliterans; Aspirin; Clinical Trials as Topic; D | 1989 |
[Evaluation of the effect of polopirin S on platelet adhesiveness in chronic peripheral circulatory failure in arteriosclerosis].
Topics: Adult; Aged; Arteriosclerosis; Aspirin; Chronic Disease; Clinical Trials as Topic; Humans; Ischemia; | 1988 |
Clinical and clinico-pharmacological trials with probon, a new analgesic.
Topics: Aged; Analgesics; Arm; Aspirin; Carboxylic Acids; Clinical Trials as Topic; Codeine; Drug Synergism; | 1972 |
Lesions in the blood supply of the papilla in experimental analgesic nephropathy.
Topics: Animals; Aspirin; Blood Vessels; Caffeine; Clinical Trials as Topic; Humans; Ischemia; Kidney; Kidne | 1968 |
161 other studies available for aspirin and Ischemia
| Article | Year |
|---|---|
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.
Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Hemor | 2022 |
Effect of postoperative antithrombotic therapy on lower extremity outcomes after infrapopliteal bypass for chronic limb-threatening ischemia.
Topics: Aged; Anticoagulants; Aspirin; Chronic Limb-Threatening Ischemia; Clopidogrel; Fibrinolytic Agents; | 2022 |
Aspirin, heparin and ischemia time in microvascular free flap surgery - their influence and an optimal anticoagulation protocol.
Topics: Anticoagulants; Aspirin; Free Tissue Flaps; Heparin; Humans; Ischemia; Postoperative Complications | 2022 |
Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack.
Topics: Aged; Aspirin; Drug Therapy, Combination; Female; Hemorrhage; Humans; Ischemia; Ischemic Attack, Tra | 2022 |
Platelet-Mediated Transfer of Cardioprotection by Remote Ischemic Conditioning and Its Abrogation by Aspirin But Not by Ticagrelor.
Topics: Animals; Aspirin; Dialysis Solutions; Humans; Infarction; Ischemia; Rats; Ticagrelor | 2023 |
P2Y12 inhibitor monotherapy is associated with superior outcomes as compared with aspirin monotherapy in chronic limb-threatening ischemia.
Topics: Aspirin; Chronic Limb-Threatening Ischemia; Humans; Ischemia; Peripheral Arterial Disease; Platelet | 2022 |
Fatal adverse events of rivaroxaban combined with aspirin: an analysis using data from VigiBase.
Topics: Aspirin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Ischemia; Male; Myocardial Infarction; Pl | 2022 |
Clinical Practice Variations in the Management of Ischemia With No Obstructive Coronary Artery Disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel | 2022 |
Association between Residential Distance from Home to Hospital and Amputation of a Lower Extremity among Peripheral Artery Disease Patients in Japan.
Topics: Amputation, Surgical; Aspirin; Hospitals; Humans; Ischemia; Japan; Limb Salvage; Lower Extremity; Pe | 2022 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
A novel de-escalation antiplatelet therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Ischemia; Percutaneous Coronary I | 2023 |
Comparison of Ticagrelor Monotherapy and Ticagrelor Plus Aspirin Among Patients With Acute Coronary Syndrome Combined With High-Risk of Gastrointestinal Bleeding After Percutaneous Coronary Intervention: A Retrospective Cohort Study.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Is | 2023 |
Digital ischaemia secondary to adalimumab-induced antiphospholipid syndrome.
Topics: Adalimumab; Anti-Inflammatory Agents; Antiphospholipid Syndrome; Aspirin; Crohn Disease; Female; Han | 2020 |
Risk factors for severe cranial ischaemic complications in giant cell arteritis.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischem | 2020 |
[Principles of angiology in lower extremity arterial disease (LEAD)].
Topics: Amputation, Surgical; Ankle Brachial Index; Aspirin; Humans; Intermittent Claudication; Ischemia; Lo | 2020 |
Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Thrombosis; Fa | 2020 |
Baseline clinical characteristics and patient profile of the TURKMI registry: Results of a nation-wide acute myocardial infarction registry in Turkey.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin Receptor Antagonists; Angiotensin-Conver | 2020 |
[In patient with symptomatic peripheral arterial disease who had undergone lower-extremity revascularization, does rivaroxaban 2.5 mg twice daily plus aspirin reduce the composite risk of acute limb ischemia, major amputation for vascular causes, myocardi
Topics: Amputation, Surgical; Aspirin; Brain Ischemia; Chocolate; Cysts; Humans; Ischemia; Ischemic Stroke; | 2020 |
Aspirin with or without statin in the treatment of endotheliitis, thrombosis, and ischemia in coronavirus disease.
Topics: Aspirin; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; En | 2020 |
Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Algorithms; Aspirin; Case-Control Studies; | 2020 |
Bilateral finger ischemia due to hand artery thrombosis caused by repeated movements.
Topics: Anti-Bacterial Agents; Aspirin; Combined Modality Therapy; Fibrinolytic Agents; Fingers; Hand; Hepar | 2021 |
Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Drug Administration Schedule; Drug Therapy, Com | 2021 |
Aspirin Blocks the Infarct-Size Limiting Effect of Ischemic Postconditioning in the Rat.
Topics: Animals; Aspirin; Ischemia; Ischemic Postconditioning; Male; Myocardial Infarction; Myocardial Reper | 2023 |
Previous hypertensive hemorrhage increases the risk for bleeding and ischemia for PCI patients on dual antiplatelet therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Clopidogrel; Drug Therapy, Combinatio | 2017 |
Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia.
Topics: Adult; Amputation, Surgical; Ankle Brachial Index; Anticoagulants; Arteritis; Aspirin; Cardiovascula | 2017 |
Ischemic Hand Complications From Intra-Arterial Injection of Sublingual Buprenorphine/Naloxone Among Patients With Opioid Dependency.
Topics: Adult; Aspirin; Buprenorphine, Naloxone Drug Combination; Clopidogrel; Female; Fibrinolytic Agents; | 2017 |
Beneficial Effect of Beraprost Sodium Plus Aspirin in the Treatment of Acute Ischemic Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Infarction; Drug Therapy, Combination; Ep | 2017 |
[Drug combination characteristics of Shenxiong glucose injection in treating ischemic cerebrovascular disease in real world].
Topics: Aspirin; Atorvastatin; Cerebrovascular Disorders; China; Clopidogrel; Drug Therapy, Combination; Dru | 2017 |
Expression of tissue inhibitor of metalloproteinases and matrix metalloproteinases in the ischemic brain of photothrombosis model mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain; Disease Models, Animal; Endothelia | 2018 |
Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Critical Il | 2018 |
Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atr | 2018 |
Ranibizumab and digital ischemia.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Angioplasty; Aspirin; Combined Modality Therapy; Female; | 2018 |
Autologous bone marrow-derived mononuclear cell therapy in Chinese patients with critical limb ischemia due to thromboangiitis obliterans: 10-year results.
Topics: Adult; Aspirin; Autografts; Bone Marrow Cells; Bone Marrow Transplantation; Disease-Free Survival; F | 2018 |
Effect of remote ischaemic conditioning on platelet aggregation and platelet turnover.
Topics: Adult; Aspirin; Blood Platelets; Healthy Volunteers; Humans; Ischemia; Male; Platelet Aggregation; T | 2018 |
Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients.
Topics: Aged; Aspirin; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Ischemia; Male | 2019 |
Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients.
Topics: Aged; Aspirin; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Ischemia; Male | 2019 |
Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients.
Topics: Aged; Aspirin; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Ischemia; Male | 2019 |
Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients.
Topics: Aged; Aspirin; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Ischemia; Male | 2019 |
Aspirin usage is associated with improved prosthetic infrainguinal bypass graft patency.
Topics: Amputation, Surgical; Aspirin; Blood Vessel Prosthesis Implantation; Comorbidity; Critical Illness; | 2014 |
Angiogenic impairment of the vascular endothelium: a novel mechanism and potential therapeutic target in muscular dystrophy.
Topics: Animals; Apoptosis; Aspirin; Carcinoma, Lewis Lung; Caveolin 1; Cell Movement; Cell Proliferation; C | 2013 |
Management of acute limb ischemia in the pediatric population.
Topics: Acute Disease; Adolescent; Anticoagulants; Aspirin; Canada; Catheterization, Peripheral; Child; Chil | 2014 |
Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera.
Topics: Adult; Aged; Aspirin; Cerebral Cortex; Erythromelalgia; Eye; Female; Follow-Up Studies; Humans; Isch | 2015 |
Statistical Perspectives on Subgroup Analysis: Testing for Heterogeneity and Evaluating Error Rate for the Complementary Subgroup.
Topics: Algorithms; Antibiotics, Antineoplastic; Antineoplastic Agents; Aspirin; Clinical Trials as Topic; C | 2015 |
A short-term risk-benefit analysis of occasional and regular use of low-dose aspirin in primary prevention of vascular diseases: a nationwide population-based study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Databases, | 2015 |
High on-treatment platelet reactivity in transcatheter aortic valve implantation patients.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Female; Humans; Ischemia; Male; Platelet Aggregation In | 2015 |
Response to dual antiplatelet therapy in patients with peripheral artery occlusive disease suffering from critical limb ischemia.
Topics: Aged; Aged, 80 and over; Area Under Curve; Aspirin; Clopidogrel; Critical Illness; Drug Resistance; | 2014 |
Prehospital aspirin administration for acute coronary syndrome (ACS) in the USA: an EMS quality assessment using the NEMSIS 2011 database.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Cross-Sectional Studies; Delivery of Health Care; Eme | 2015 |
Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease.
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; California; Cardiovascular Diseases; | 2015 |
Platelet reactivity in MitraClip patients.
Topics: Aspirin; Clopidogrel; Cohort Studies; Heart Valve Prosthesis Implantation; Hemorrhage; Ischemia; Mit | 2016 |
Effect of remote ischaemic conditioning on coagulation and fibrinolysis.
Topics: Adult; Arm; Aspirin; Blood Coagulation; Blood Coagulation Tests; Cross-Over Studies; Fibrin Clot Lys | 2016 |
Dual Antiplatelet Therapy in the Prevention of Recurrent Ischemic Events.
Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Humans; Ischemia; Platelet Aggregation Inhibitor | 2016 |
Concurrent Lower Gastrointestinal Bleeding Risk and Myocardial Ischemic Risk: Resume Aspirin or Not?
Topics: Aspirin; Gastrointestinal Hemorrhage; Humans; Ischemia; Platelet Aggregation Inhibitors; Risk | 2016 |
Dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization.
Topics: Aged; Aged, 80 and over; Aspirin; Chi-Square Distribution; Critical Illness; Drug Therapy, Combinati | 2016 |
[Prevalence and prognosis of aspirin resistance in critical limb ischemia patients].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Drug Resistance; Ex | 2016 |
Impact of different antithrombotics on the microcirculation and viability of perforator-based ischaemic skin flaps in a small animal model.
Topics: Animals; Aspirin; Clopidogrel; Disease Models, Animal; Fibrinolytic Agents; Graft Survival; Heparin; | 2016 |
Editor's Choice - Dual Antiplatelet Therapy Improves Outcome in Diabetic Patients Undergoing Endovascular Femoropopliteal Stenting for Critical Limb Ischaemia.
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Clopidogrel; Constriction, Pathologic | 2017 |
[Digital ischemia in a gardener: is rose cutting a vascular risk factor?].
Topics: Alprostadil; Aneurysm; Anticoagulants; Aspirin; Diagnosis, Differential; Female; Finger Injuries; Fi | 2008 |
[Brain hypoperfusion revealed by an ocular ischemic syndrome].
Topics: Antihypertensive Agents; Aspirin; Atorvastatin; Brain Ischemia; Carotid Artery Thrombosis; Ciliary B | 2008 |
High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Cell Size; Female; Giant Cell Art | 2009 |
Aspirin vs anticoagulation in carotid artery dissection: a study of 298 patients.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Artery, Internal, Dissection; Female; Follow-Up Stu | 2009 |
The cyclooxygenase-2 selective inhibitor, etodolac, but not aspirin reduces neovascularization in a murine ischemic hind limb model.
Topics: Animals; Aspirin; Bone Marrow Cells; Cell Transplantation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclo | 2010 |
Antiplatelet therapy in the treatment of Takayasu arteritis.
Topics: Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; Humans; Ischemia; Platelet Aggregatio | 2010 |
Do not adjust the platelet count in light transmittance aggregometry when predicting thrombotic events after percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Humans; Ische | 2010 |
Delphi-consensus weights for ischemic and bleeding events to be included in a composite outcome for RCTs in thrombosis prevention.
Topics: Aspirin; Hemorrhage; Humans; Ischemia; Randomized Controlled Trials as Topic; Stroke; Thrombosis; Tr | 2011 |
[Preoperative analysis of platelet aggregability in carotid surgery].
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Arteries; Clopidogrel; Endarterectomy, Carotid; Female; Hu | 2011 |
Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia.
Topics: Aspirin; Female; Humans; Ischemia; Leg; Male; Platelet Aggregation Inhibitors; Ticlopidine | 2014 |
Reply to letter: "Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia".
Topics: Aspirin; Female; Humans; Ischemia; Leg; Male; Platelet Aggregation Inhibitors; Ticlopidine | 2014 |
Dose-dependent effect of early antiplatelet therapy in acute ischaemic stroke.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Body Mass Index; Brain Ischemia; Clopidogrel; Dose-Response | 2012 |
Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study.
Topics: Aged; Alabama; Antithrombins; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Elective Surgi | 2012 |
Long-term risk of vascular events after peripheral bypass surgery. A cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amputation, Surgical; Anticoagulants; Aspirin; Blood | 2012 |
Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry).
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Atherectomy; Atorvastatin; Cardiovasc | 2013 |
Can the diagnosis of NSAID-induced or Hp-associated gastric ulceration be predicted from histology?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy; Comorbidity; Diagnosis, Differential | 2002 |
Acute peripheral arterial ischemia and suspected aortic dissection: usefulness of transesophageal echocardiography in differential diagnosis with aortic thrombosis.
Topics: Acute Disease; Adult; Aged; Amputation, Surgical; Anticoagulants; Aortic Diseases; Arterial Occlusiv | 2002 |
Use of dacron vascular prosthesis impregnated with salts of silver, in treatment of extraanatomical axilla-femoral by-pass's infection. Infections in vascular surgery.
Topics: Aged; Aneurysm, Infected; Anti-Bacterial Agents; Aspirin; Blood Vessel Prosthesis; Coated Materials, | 2002 |
[Oxygen-carrying solutions improve tissue oxygenation in striated skin muscle subjected to critical ischemia].
Topics: Animals; Aspirin; Blood Substitutes; Capillaries; Cricetinae; Hemoglobins; Ischemia; Mesocricetus; M | 2003 |
Implications of reactive oxygen species and cytokines in gastroprotection against stress-induced gastric damage by nitric oxide releasing aspirin.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Central Nervous | 2003 |
Single dose of acetylsalicylic acid prevents thromboxane release after tourniquet ischemia.
Topics: Adult; Aspirin; Humans; Ischemia; Thromboxane B2; Tourniquets | 2003 |
ISCHEMIC ARM PAIN AND THE NONNARCOTIC ANALGESIC MEFENAMIC ACID, N-(2,3-XYLYL)ANTHRANILIC ACID.
Topics: Analgesics; Analgesics, Non-Narcotic; Antipyretics; Arm; Aspirin; Biomedical Research; Ischemia; Mef | 1965 |
The efficacy of aspirin in patients undergoing infra-inguinal bypass and identification of high risk patients.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Vessel Prosthesis Implantation; Graft Occlusion, Vasc | 2003 |
Aspirin resistance.
Topics: Aspirin; Drug Resistance; Humans; Ischemia; Platelet Aggregation Inhibitors; Recurrence | 2004 |
Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Aspirin; Blindness; Drug Therapy, Combination; Fe | 2004 |
Aspirin withdrawal and acute lower limb ischemia.
Topics: Aged; Aged, 80 and over; Arterial Occlusive Diseases; Aspirin; Chronic Disease; Female; Humans; Isch | 2004 |
Screening for proximal deep vein thrombosis after acute ischemic stroke: a prospective study using clinical factors and plasma D-dimers.
Topics: Age Factors; Aged; Aspirin; Bandages; Female; Fibrin Fibrinogen Degradation Products; Humans; Ischem | 2004 |
Endovascular stent-assisted angioplasty in the management of traumatic internal carotid artery dissections.
Topics: Adult; Angiography; Angioplasty; Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis I | 2005 |
Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease.
Topics: Aged; Alleles; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Clopidogrel; Cohort Studies; Ex | 2005 |
Reversible ischaemia after raising a radial forearm flap with ulceration of three fingers in a cigarette smoker.
Topics: Anticoagulants; Aspirin; Carcinoma, Squamous Cell; Fascia; Fibrinolytic Agents; Fingers; Forearm; He | 2006 |
Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community-based study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Blood Pressur | 2005 |
Acute pain in the tip of the index finger.
Topics: Acute Disease; Amlodipine; Arterial Occlusive Diseases; Aspirin; Cyanosis; Diagnostic Errors; Female | 2005 |
[NSAID-colonopathy].
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colitis; Colon; Diagnosis, Differentia | 2006 |
Infantile Kawasaki disease and peripheral gangrene.
Topics: Abciximab; Amputation, Surgical; Anti-Bacterial Agents; Antibodies, Monoclonal; Anticoagulants; Anti | 2006 |
Surgical revascularisation in patients with severe limb ischaemia induces a pro-thrombotic state.
Topics: Aged; Aged, 80 and over; Antithrombin III; Arterial Occlusive Diseases; Aspirin; Blood Coagulation; | 2006 |
Could discontinuation of aspirin therapy be a trigger for stroke?
Topics: Aspirin; Humans; Ischemia; Platelet Aggregation Inhibitors; Risk; Stroke; Substance Withdrawal Syndr | 2006 |
[Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark].
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Bypass; Coronary | 2006 |
Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thromboph
Topics: Aged; Anticoagulants; Aspirin; Drug Resistance; Erythromelalgia; Female; Humans; Ischemia; Male; Mic | 2006 |
Platelet monocyte aggregates and monocyte chemoattractant protein-1 are not inhibited by aspirin in critical limb ischaemia.
Topics: Aged; Aged, 80 and over; Angiography; Aspirin; Biomarkers; Chemokine CCL2; Enzyme-Linked Immunosorbe | 2007 |
Redo pedal bypass surgery after pedal graft failure: gain or gadget?
Topics: Aged; Anastomosis, Surgical; Anticoagulants; Arteries; Aspirin; Blood Vessel Prosthesis; Blood Vesse | 2007 |
Intensifying platelet inhibition--navigating between Scylla and Charybdis.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischem | 2007 |
Prolonged transient hand ischaemia secondary to a penicillin skin test.
Topics: Aspirin; Calcium Channel Blockers; Cyanosis; Drug Hypersensitivity; Drug Therapy, Combination; Fibri | 2007 |
Consensus document on intermittent claudication from the Central European Vascular Forum 1st edition - Abano Terme (Italy) - May 2005 2nd revision - Portroz (Slovenia) September 2007.
Topics: Aspirin; Carotid Stenosis; Clopidogrel; Disease Progression; Exercise Test; Humans; Intermittent Cla | 2008 |
Factors determining the site of chronic gastroduodenal ulcers.
Topics: Animals; Aspirin; Chronic Disease; Diet; Digestive System; Duodenum; Gastric Acid; Gastric Mucins; G | 1982 |
Effect of cimetidine on net ion fluxes across the rat gastric mucosa during mucosal damage after gastric ischemia and after intravenous acetylsalicylic acid.
Topics: Animals; Aspirin; Biological Transport; Chromium Radioisotopes; Cimetidine; Drug Interactions; Elect | 1984 |
Percutaneous transluminal coronary angioplasty at a community hospital--initial experience.
Topics: Adult; Angioplasty, Balloon; Aspirin; Coronary Vessels; Dipyridamole; Female; Hospitals, Community; | 1982 |
Forearm ischaemia as a test of prostacyclin production: studies in normal subjects and in patients with diabetes mellitus.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aspirin; Blood Glucose; Diabetic Retinopathy; Forearm; Gas Chro | 1981 |
Role of gastric mucosal folds in formation of focal ulcers in the rat.
Topics: Action Potentials; Animals; Aspirin; Disease Models, Animal; Gastric Mucosa; Ischemia; Permeability; | 1982 |
Effect of platelet aggregation inhibitors on the rate of thrombectomy following arterial reconstructions with Gore-Tex prostheses: a retrospective study.
Topics: Aspirin; Blood Vessel Prosthesis; Dipyridamole; Humans; Ischemia; Leg; Platelet Aggregation; Postope | 1982 |
Gangrene of the toes with palpable peripheral pulses.
Topics: Aged; Aspirin; Dipyridamole; Drug Therapy, Combination; Female; Gangrene; Humans; Ischemia; Male; Mi | 1981 |
Practical impact of hemorheology on the treatment of chronic peripheral ischemia.
Topics: Ancrod; Aspirin; Blood Viscosity; Chronic Disease; Erythrocyte Count; Fibrinogen; Humans; Intermitte | 1981 |
Leg pain and platelet aggregates in thrombocythemic myeloproliferative disease.
Topics: Aged; Aspirin; Female; Foot; Humans; Ischemia; Male; Microcirculation; Middle Aged; Myeloproliferati | 1980 |
Focal microcirculatory changes during the production of aspirin-induced gastric mucosal erosions.
Topics: Animals; Aspirin; Dogs; Female; Gastric Mucosa; Ischemia; Male; Microcirculation; Microspheres; Stom | 1981 |
Aspirin improves the outcome of intra-arterial thrombolysis with tissue plasminogen activator. Thrombolysis Study Group.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Humans; Infusions, Intravenous; Ischemia; Leg; Middle Aged; | 1995 |
[The activity of the lymphatic vessels under conditions of experimental stress exposures].
Topics: Alcohols; Animals; Aspirin; Cattle; Dose-Response Relationship, Drug; Drug Evaluation; Drug Evaluati | 1994 |
Differential effect of 5- and 15-lipoxygenase products on ischemically sensitive abdominal visceral afferents.
Topics: Abdomen; Animals; Aspirin; Cats; Electrophysiology; Ischemia; Leukotriene B4; Lipoxygenase; Naphthal | 1995 |
Diaspirin crosslinked hemoglobin (DCLHb): absence of increased free radical generation following administration in a rabbit model of renal ischemia and reperfusion.
Topics: Animals; Aspirin; Cyclic N-Oxides; Disease Models, Animal; Electron Spin Resonance Spectroscopy; Fre | 1995 |
Anterior ischemic optic neuropathy secondary to interferon alfa.
Topics: Acute Disease; Adult; Aspirin; Carcinoma, Renal Cell; Fundus Oculi; Humans; Interferon-alpha; Ischem | 1995 |
[Cutaneous manifestations of essential thrombocythemia. Erythromelalgia, ischemic acrocyanosis, livedo racemosa].
Topics: Aged; Aspirin; Cyanosis; Diagnosis, Differential; Erythromelalgia; Female; Humans; Ischemia; Skin; T | 1995 |
Symmetrical peripheral gangrene (purpura fulminans) complicating pneumococcal sepsis.
Topics: Adrenal Cortex Hormones; Amputation, Surgical; Aspirin; Debridement; Dextrans; Dopamine; Fingers; Fo | 1993 |
Endogenous BK stimulates ischemically sensitive abdominal visceral C fiber afferents through kinin B2 receptors.
Topics: Afferent Pathways; Animals; Aspirin; Bradykinin; Bradykinin Receptor Antagonists; Captopril; Cats; I | 1994 |
[Arterial occlusion in cutis marmorata teleangiectatica congenita].
Topics: Adolescent; Angiography; Arterial Occlusive Diseases; Arteriovenous Malformations; Aspirin; Dose-Res | 1995 |
Diaspirin cross-linked hemoglobin improves neurological outcome following reversible but not irreversible CNS ischemia in rabbits.
Topics: Animals; Aspirin; Hemoglobins; Intracranial Embolism and Thrombosis; Ischemia; Male; Nervous System; | 1994 |
[Optic neuropathy in type-1 diabetes and acetylsalicylic acid-refractory thrombocyte activation].
Topics: Adult; Aspirin; Chronic Disease; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Diabetic Neuropa | 1993 |
Aspirin increases tissue oedema after skeletal muscle ischaemia and reperfusion.
Topics: Administration, Oral; Animals; Aspirin; Cell Movement; Disease Models, Animal; Edema; Hindlimb; Infu | 1996 |
Antiphospholipid syndrome presenting as episodic limb ischaemia.
Topics: Acute Disease; Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Aspirin; Child, Preschool; Ex | 1996 |
Postischemic hyperemia in subjects with lower limbs obstructive arteriopathy: role of PGI2 and endothelin.
Topics: Aged; Arteriosclerosis; Aspirin; Endothelins; Epoprostenol; Hemodynamics; Humans; Hyperemia; Ilopros | 1997 |
Aspirin versus clopidogrel: the wrong question?
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Humans; Ischemia; Myocardial Infarction; Platelet A | 1997 |
Pregnancy in a patient with essential thrombocytosis.
Topics: Aspirin; Female; Humans; Ischemia; Placenta; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy C | 1997 |
In vitro model(s) for the percutaneous delivery of active tissue repair agents.
Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents; Aspirin; Bridged Bicyclo Compounds, He | 1997 |
[Isolated axial lateral pulse as a sign of latero-bulbar ischemia: clinical topographic correlation].
Topics: Adult; Aged; Aspirin; Cerebellar Ataxia; Female; Humans; Ischemia; Male; Medulla Oblongata; Middle A | 1997 |
Carotid-subclavian bypass for subclavian artery revascularization: long-term follow-up and effect of antiplatelet therapy.
Topics: Adult; Aged; Angiography; Anticoagulants; Arm; Arterial Occlusive Diseases; Aspirin; Blood Vessel Pr | 1998 |
Acetylsalicylate administered during simulated ischemia reduces the recovery of neuronal function in the in vitro rabbit retina.
Topics: Action Potentials; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relation | 1998 |
Attenuation of postischemic reperfusion injury in striated skin muscle by diaspirin-cross-linked Hb.
Topics: Animals; Arterioles; Aspirin; Blood Flow Velocity; Blood Pressure; Blood Substitutes; Cricetinae; En | 1998 |
[Substantiation of complex surgical treatment of inguinal hernia in children based on pathogenetic criteria].
Topics: Age Factors; Antioxidants; Ascorbic Acid; Aspirin; Blood-Testis Barrier; Child; Dipyridamole; Hernia | 1998 |
Effect of diaspirin cross-linked hemoglobin on normal and postischemic microcirculation of the rat pancreas.
Topics: Animals; Aspirin; Cell Movement; Granulocytes; Hemoglobins; Ischemia; Male; Microcirculation; Pancre | 1999 |
Clopidogrel: a novel antiplatelet agent.
Topics: Adenosine Diphosphate; Aspirin; Clopidogrel; Humans; Ischemia; Myocardial Infarction; Platelet Aggre | 1999 |
Reflex cardiovascular response to brief abdominal visceral ischemia is mediated in part by prostaglandins.
Topics: Abdomen; Animals; Aspirin; Blood Pressure; Cardiovascular Agents; Cardiovascular System; Cats; Cyclo | 1999 |
Aspirin use and the prevention of acute ischemic cranial nerve palsy.
Topics: Acute Disease; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Cranial Nerve Diseases; Crani | 2000 |
Aggrenox and stress testing.
Topics: Adenosine; Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Humans; | 2001 |
[Occlusion of the arteries of the fingers after hyperextension trauma].
Topics: Adult; Arterial Occlusive Diseases; Aspirin; Athletic Injuries; Female; Finger Injuries; Fingers; He | 2002 |
Physiological parameters of the gastric mucosal barrier.
Topics: Aspirin; Capillary Permeability; Diffusion; Gastric Juice; Gastric Mucosa; Histamine; Humans; Hydrog | 1976 |
Lavage to remove enteric-coated aspirin and gastric outlet obstruction.
Topics: Aspirin; Bicarbonates; Duodenal Ulcer; Humans; Hydrogen-Ion Concentration; Ischemia; Male; Pyloric S | 1977 |
Stress ulceration and the gastric mucosal barrier.
Topics: Animals; Aspirin; Bile Acids and Salts; Cats; Disease Models, Animal; Ethanol; Gastric Acidity Deter | 1975 |
Preventing the prostaglandin effect on dermal ischemia in the burn wound.
Topics: Animals; Aspirin; Burns; Female; Guinea Pigs; Indomethacin; Ischemia; Methylprednisolone; Prostaglan | 1978 |
The evaluation of analgesic drugs. The case for experimental methods.
Topics: Analgesics; Aspirin; Drug Evaluation; Electroshock; Humans; Ischemia; Morphine; Pain | 1979 |
Aspirin damage to ischemic gastric mucosa in shocked cats.
Topics: Administration, Topical; Animals; Aspirin; Cardiac Output; Cats; Female; Gastric Mucosa; Ischemia; M | 1979 |
[Ischemic lesions in polycythaemia vera (author's transl)].
Topics: Aspirin; Dipyridamole; Female; Foot; Humans; Ischemia; Male; Middle Aged; Pain; Polycythemia Vera; S | 1977 |
Using antithrombotic therapy in ischemic cerebrovascular disease.
Topics: Aspirin; Brain; Cerebrovascular Disorders; Dipyridamole; Fibrinolytic Agents; Heparin; Humans; Intra | 1977 |
The emergency cold leg.
Topics: Aspirin; Dextrans; Embolism; Emergencies; Femoral Artery; Heparin; Humans; Ischemia; Leg; Methods; P | 1975 |
Small intestinal permeability. 1. Effects of ischaemia and exposure to acetyl salicylate.
Topics: Animals; Aspirin; Basement Membrane; Cell Membrane Permeability; Creatinine; Female; Intestinal Muco | 1976 |
Antithrombotic therapy for lower extremity bypass.
Topics: Aspirin; Humans; Ischemia; Leg; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; | 1992 |
Hydrogen peroxide-induced cardiovascular reflexes. Role of hydroxyl radicals.
Topics: Animals; Aspirin; Blood Pressure; Cardiovascular Physiological Phenomena; Cardiovascular System; Cat | 1992 |
Usefulness of antiplatelet drugs in the management of heparin-associated thrombocytopenia and thrombosis.
Topics: Aged; Aorta, Abdominal; Aspirin; Dipyridamole; Female; Femoral Vein; Heparin; Humans; Iliac Artery; | 1991 |
Ischemically sensitive abdominal visceral afferents: response to cyclooxygenase blockade.
Topics: Abdomen; Afferent Pathways; Animals; Aspirin; Cats; Cyclooxygenase Inhibitors; Gallbladder; Indometh | 1991 |
[Rate of recurrence following PTA of pelvic-leg arteries in relation to selected risk factors and antithrombotic after care].
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Combined Modality Therapy; Coumarins; Fo | 1991 |
Plasmapheresis in the management of heparin-associated thrombocytopenia with thrombosis.
Topics: Amputation, Surgical; Aspirin; Dextrans; Female; Heparin; Humans; Intermittent Claudication; Ischemi | 1988 |
Qualitative and quantitative studies on the nucleotides of intestinal mucosa.
Topics: Animals; Aspirin; Chromatography, High Pressure Liquid; Indomethacin; Intestinal Mucosa; Ischemia; J | 1989 |
Bilateral loss of vision in bright light.
Topics: Aged; Aged, 80 and over; Aspirin; Blindness; Carotid Artery Diseases; Carotid Artery, External; Caro | 1989 |
The contribution of vascular obstruction to the functional defect that follows renal ischemia.
Topics: Animals; Aspirin; Glomerular Filtration Rate; Hematocrit; Heparin; Ischemia; Kidney Medulla; Male; P | 1987 |
Focal gastric mucosal blood flow in aspirin-induced ulceration.
Topics: Acute Disease; Animals; Aspirin; Dogs; Electrodes; Female; Gastric Mucosa; Hydrogen; Ischemia; Male; | 1987 |
Injectable aspirin and mepyramine abolish post-ischaemic hyperalgesia in rats.
Topics: Aminopyridines; Animals; Aspirin; Histamine; Hyperalgesia; Hyperesthesia; Ischemia; Male; Prostaglan | 1986 |
Experimental digital replantation after prolonged cooling.
Topics: Animals; Arteries; Aspirin; Autopsy; Cold Temperature; Dipyridamole; Fingers; Graft Rejection; Haplo | 1974 |
Mesenteric vasoconstriction after endotoxin administration in cats pretreated with aspirin.
Topics: Angiotensin II; Animals; Aspirin; Blood Platelets; Blood Pressure; Cats; Endotoxins; Heart Failure; | 1971 |
The gastric mucosal barrier in thermally injured patients: correlation with gastroduodenal endoscopy.
Topics: Adult; Aspirin; Burns; Gastric Mucosa; Gastroscopy; Humans; Ischemia; Lithium; Permeability | 1974 |
Inhibition of platelet-induced thrombus formation.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Brain Diseases; Dipyridamole; Epinephrin | 1974 |
Comparison of flufenamic acid with aspirin and paracetamol in terms of gastrointestinal blood loss.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Chromium Isotopes; Fe | 1966 |
[Round table discussion of gastric ulcer].
Topics: Aspirin; Cortisone; Duodenal Diseases; Gastric Juice; Gastritis; Humans; Ischemia; Stomach Ulcer; St | 1968 |